govx20190630

0001437749-19-016606.txt : 20190813 0001437749-19-016606.hdr.sgml : 20190813 20190813172733 ACCESSION NUMBER: 0001437749-19-016606 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GeoVax Labs, Inc. CENTRAL INDEX KEY: 0000832489 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 870455038 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52091 FILM NUMBER: 191021867 BUSINESS ADDRESS: STREET 1: 1900 LAKE PARK DRIVE STREET 2: SUITE 380 CITY: SMYRNA STATE: 2Q ZIP: 30080 BUSINESS PHONE: 678-384-7220 MAIL ADDRESS: STREET 1: 1900 LAKE PARK DRIVE STREET 2: SUITE 380 CITY: SMYRNA STATE: 2Q ZIP: 30080 FORMER COMPANY: FORMER CONFORMED NAME: Geovax Labs, Inc. DATE OF NAME CHANGE: 20061002 FORMER COMPANY: FORMER CONFORMED NAME: DAUPHIN TECHNOLOGY INC DATE OF NAME CHANGE: 19940826 FORMER COMPANY: FORMER CONFORMED NAME: SUCCESSO INC DATE OF NAME CHANGE: 19910410 10-Q 1 govx20190630_10q.htm FORM 10-Q govx20190630_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended June 30, 2019

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from to

Commission file number 000-52091

GEOVAX LABS, INC.

(Exact name of Registrant as specified in its charter)

Delaware		87-0455038
(State or other jurisdiction		(I.R.S. Employer Identification No.)
of incorporation or organization)

1900 Lake Park Drive, Suite 380
Smyrna, Georgia		30080
(Address of principal executive offices)		(Zip Code)

(678) 384-7220

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Emerging growth company	☐
Smaller reporting company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

As of August 13, 2019, 2,677,584 shares of the Registrant’s common stock, $.001 par value, were issued and outstanding.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION

Item 1	Condensed Consolidated Financial Statements:
	Condensed Consolidated Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018	1
	Condensed Consolidated Statements of Operations for the three-month and six-month periods ended June 30, 2019 and 2018 (unaudited)	2
	Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) for the three-month and six-month periods ended June 30, 2019 and 2018 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2019 and 2018 (unaudited)	4
	Notes to Condensed Consolidated Financial Statements (unaudited)	5

Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	11

Item 3	Quantitative and Qualitative Disclosures about Market Risk	16

Item 4	Controls and Procedures	16

PART II – OTHER INFORMATION

Item 1	Legal Proceedings	17

Item 1A	Risk Factors	17

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	17

Item 3	Defaults Upon Senior Securities	17

Item 4	Mine Safety Disclosures	17

Item 5	Other Information	17

Item 6	Exhibits	18

SIGNATURES		19

Part I -- FINANCIAL INFORMATION

Item 1

Financial Statements

GEOVAX LABS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2019			2018
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	216,411		$	259,701
Grant funds and other receivables		64,246			121,814
Prepaid expenses and other current assets		39,139			238,189
Total current assets		319,796			619,704
Property and equipment, net (Note 5)		11,827			11,350
Deposits		11,010			11,010

Total assets	$	342,633		$	642,064

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
Current liabilities:
Accounts payable	$	116,207		$	125,859
Accrued expenses (Note 6)		1,510,268			1,238,552
Current portion of notes payable (Note 7)		12,500			260,420
Total current liabilities		1,638,975			1,624,831
Note payable, net of current portion (Note 7)		32,291			39,580
Total liabilities		1,671,266			1,664,411

Commitments (Note 8)

Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value:
Authorized shares – 10,000,000
Issued and outstanding shares – 3,402 and 3,450 at June 30, 2019 and December 31, 2018, respectively (Note 9)		2,337,867			1,971,333
Common stock, $.001 par value:
Authorized shares – 600,000,000
Issued and outstanding shares – 813,916 and 437,807 at June 30, 2019 and December 31, 2018, respectively		814			438
Additional paid-in capital		38,165,172			37,482,766
Accumulated deficit		(41,832,486	)		(40,476,884	)
Total stockholders’ equity (deficiency)		(1,328,633	)		(1,022,347	)

Total liabilities and stockholders’ equity (deficiency)	$	342,633		$	642,064

See accompanying notes to condensed consolidated financial statements.

GEOVAX LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Grant and collaboration revenue	$	209,941		$	93,265		$	574,173		$	314,564

Operating expenses:
Research and development		451,227			372,202			1,006,945			859,196
General and administrative		412,650			359,197			922,714			716,425
Total operating expenses		863,877			731,399			1,929,659			1,575,621

Loss from operations		(653,936	)		(638,134	)		(1,355,486	)		(1,261,057	)

Other income (expense):
Interest income		881			1,716			2,105			3,034
Interest expense		(1,093	)		(625	)		(2,221	)		(833	)
Total other income (expense)		(212	)		1,091			(116	)		2,201

Net loss	$	(654,148	)	$	(637,043	)	$	(1,355,602	)	$	(1,258,856	)

Basic and diluted:
Loss per common share	$	(1.01	)	$	(2.05	)	$	(2.37	)	$	(4.50	)
Weighted averages shares outstanding		649,486			310,419			571,032			279,551

See accompanying notes to condensed consolidated financial statements.

GEOVAX LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIENCY)

(Unaudited)

	Three-Month and Six-Month Periods Ended June 30, 2019
																Total
											Additional					Stockholders’
	Preferred Stock (Note 9)						Common Stock				Paid-in		Accumulated			Equity
	Shares			Amount			Shares		Amount		Capital		Deficit			(Deficiency)
Balance at December 31, 2018		3,450		$	1,971,333			437,807	$	438	$	37,482,766	$	(40,476,884	)	$	(1,022,347	)
Sale of convertible preferred stock for cash and cancellation of note payable		500			404,250			-		-		85,750		-			490,000
Conversion of preferred stock to common stock		(767	)		(303,475	)		118,280		118		303,357		-			-
Fractional shares issuable upon reverse stock split		-			-			402		-		-		-			-
Stock option expense		-			-			-		-		26,652		-			26,652
Net loss for the three months ended March 31, 2019		-			-			-		-		-		(701,454	)		(701,454	)
Balance at March 31, 2019		3,183			2,072,108			556,489		556		37,898,525		(41,178,338	)		(1,207,149	)
Sale of convertible preferred stock for cash		500			438,700			-		-		61,300		-			500,000
Conversion of preferred stock to common stock		(281	)		(172,941	)		253,300		254		172,687		-			-
Fractional shares issuable upon reverse stock split		-			-			-		-		-		-			-
Issuance of common stock for services		-			-			4,127		4		5,996		-			6,000
Stock option expense		-			-			-		-		26,664		-			26,664
Net loss for the three months ended June 30, 2019		-			-			-		-		-		(654,148	)		(654,148	)
Balance at June 30, 2019		3,402		$	2,337,867			813,916	$	814	$	38,165,172	$	(41,832,486	)	$	(1,328,633	)

	Three-Month and Six-Month Periods Ended June 30, 2018
																Total
											Additional					Stockholders’
	Preferred Stock (Note 9)						Common Stock				Paid-in		Accumulated			Equity
	Shares			Amount			Shares		Amount		Capital		Deficit			(Deficiency)
Balance at December 31, 2017		3,670		$	1,899,085			213,474	$	213	$	35,696,435	$	(37,916,790	)	$	(321,057	)
Sale of convertible preferred stock for cash		600			590,000			-		-		-		-			590,000
Conversion of preferred stock to common stock		(450	)		(441,000	)		60,000		60		440,940		-			-
Issuance of common stock for services		-			-			10,000		10		199,990		-			200,000
Stock option expense		-			-			-		-		23,978					23,978
Net loss for the three months ended March 31, 2018		-			-			-		-		-		(621,813	)		(621,813	)
Balance at March 31, 2018		3,820			2,048,085			283,474		283		36,361,343		(38,538,603	)		(128,892	)
Conversion of preferred stock to common stock		(345	)		(338,100	)		46,000		46		338,054		-			-
Stock option expense		-			-			-		-		23,221		-			23,221
Net loss for the three months ended June 30, 2018		-			-			-		-		-		(637,043	)		(637,043	)
Balance at June 30, 2018		3,475		$	1,709,985			329,474	$	329	$	36,722,618	$	(39,175,646	)	$	(742,714	)

See accompanying notes to consolidated financial statements

GEOVAX LABS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended June 30,
	2019			2018
Cash flows from operating activities:
Net loss	$	(1,355,602	)	$	(1,258,856	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,795			9,930
Stock-based compensation expense		258,396			132,913
Changes in assets and liabilities:
Grant funds and other receivables		57,568			59,758
Prepaid expenses and other current assets		(30	)		41,695
Accounts payable and accrued expenses		262,064			252,802
Total adjustments		581,793			497,098
Net cash used in operating activities		(773,809	)		(761,758	)

Cash flows from investing activities:
Purchase of property and equipment		(4,272	)		-
Net cash used in investing activities		(4,272	)		-

Cash flows from financing activities:
Net proceeds from sale of preferred stock		740,000			590,000
Proceeds from issuance of note payable		-			50,000
Principal repayment of note payable		(5,209	)		-
Net cash provided by financing activities		734,791			640,000

Net decrease in cash and cash equivalents		(43,290	)		(121,758	)
Cash and cash equivalents at beginning of period		259,701			312,727

Cash and cash equivalents at end of period	$	216,411		$	190,969

Supplemental disclosure of non-cash financing activities:

During the six months ended June 30, 2019, 1,563 shares of Series C Convertible Preferred Stock and 1,200 shares of Series E Convertible Preferred Stock were exchanged for 2,763 shares of Series F Convertible Preferred Stock, 250 shares of Series G Convertible Preferred Stock were issued in exchange for cancellation of $250,000 of term notes payable, 587 shares of Series C Convertible Preferred Stock were converted into 78,280 shares of common stock, and 461 shares of Series F Convertible Preferred Stock were converted into 293,300 shares of common stock.

During the six months ended June 30, 2018, 795 shares of Series D Convertible Preferred Stock were converted into 106,000 shares of common stock.

See accompanying notes to condensed consolidated financial statements.

GEOVAX LABS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2019

(unaudited)

1. Description of Business

GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (Modified Vaccinia Ankara Virus-Like Particle, or “MVA-VLP”). Our recombinant MVA vector expresses target proteins on highly immunogenic VLPs in the person being vaccinated, resulting in durable immune responses while providing the safety characteristics of the replication-defective MVA vector. Important attributes of GeoVax vaccines include single dose, no adjuvant, durable immunity, extensive safety and cost-effective manufacturing.

Our current development programs are focused on preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV); preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa fever), Zika virus and malaria; a therapeutic vaccine for chronic hepatitis B virus infections; and preventive and therapeutic vaccines for multiple solid tumor cancers. Our most advanced vaccine program is focused on the clade B subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan and Australia; this program is currently undergoing human clinical trials.

Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.

We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners.

GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in metropolitan Atlanta, Georgia.

2. Basis of Presentation

The accompanying condensed consolidated financial statements at June 30, 2019 and for the three-month and six-month periods ended June 30, 2019 and 2018 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.

As described in Note 10, effective April 30, 2019, we enacted a one-for-five hundred reverse stock split of our common stock. The accompanying financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split.

Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities.

We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 13 will be sufficient to continue our planned operations into the first quarter of 2020. Due to our history of operating losses and our continuing need for capital to conduct our research and development activities, there is substantial doubt concerning our ability to operate as a going concern beyond that date. We are currently exploring sources of capital through additional government grants and corporate collaborations. We also intend to secure additional funds through sales of our equity securities or by other means. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern. Additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we will be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.

3. Significant Accounting Policies and Recent Accounting Pronouncements

We disclosed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 those accounting policies that we consider significant in determining our results of operations and financial position. Other than as described below, there have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K.

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2016-02, Leases (ASU 2016-02). ASU 2016-02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to classify leases as either financing or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to prior guidance for operating leases. We adopted ASU 2016-02 effective January 1, 2019; such adoption had no material impact on our financial statements, given that the noncancelable term of our current lease is less than 12 months (see Note 8).

There have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2019, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which we expect to have a material impact on our financial statements.

4. Basic and Diluted Loss Per Common Share

Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled 376,130 and 351,684 shares for the three-month and six-month periods ended June 30, 2019, respectively, as compared to 51,270 and 51,155 shares for the three-month and six-month periods ended June 30, 2018, respectively.

5. Property and Equipment

Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2019 and December 31, 2018:

	June 30, 2019			December 31, 2018
Laboratory equipment	$	534,578		$	530,306
Leasehold improvements		115,605			115,605
Other furniture, fixtures & equipment		28,685			28,685
Total property and equipment		678,868			674,596
Accumulated depreciation and amortization		(667,041	)		(663,246	)
Property and equipment, net	$	11,827		$	11,350

6. Accrued Expenses

Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2019 and December 31, 2018:

	June 30, 2019		December 31, 2018
Accrued management salaries	$	1,128,425	$	924,509
Accrued directors’ fees		361,470		295,670
Other accrued expenses		20,373		18,373
Total accrued expenses	$	1,510,268	$	1,238,552

7. Notes Payable

On February 28, 2018, we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a five-year Senior Promissory Note (the “GRA Note”) to GRA in exchange for $50,000. The GRA Note bears an annual interest rate of 5%, payable monthly, with principal repayments beginning in the second year. Principal repayments are expected to be $6,250 for the remainder of 2019, $12,500 in 2020, 2021 and 2022, and $2,083 in 2023. Interest expense related to the GRA Note for the three-month and six-month periods ended June 30, 2019 was $586 and $1,207, respectively, as compared to $625 and $833, respectively, for the same periods of 2018.

On December 27, 2018, we issued short-term non-interest-bearing Term Promissory Notes (the “Term Notes”) to two current investors in exchange for an aggregate of $250,000. In February 2019, the Term Notes were cancelled in exchange for shares of our convertible preferred stock (see Note 9).

8. Commitments

Lease Agreement

We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2019, with annual extension options through December 31, 2022. Rent expense for the for the three-month and six-month periods ended June 30, 2019 was $40,316 and $80,633, respectively, as compared to $39,136 and $78,273, respectively, for the same periods of 2018. Future minimum lease payments total $80,633 for the remainder of 2019. Our current intention is to exercise our option to extend the lease at least for the subsequent one-year renewal period, subject to our landlord’s right to cancel the extension period 90 days prior to its commencement.

Other Commitments

In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of June 30, 2019, there are approximately $459,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2019. We expect this entire amount to be reimbursable to us pursuant to existing government grants.

9. Preferred Stock

Preferred Stock Summary

We are authorized to issue up to 10,000,000 shares of our Preferred Stock, $.01 par value, which may be issued in one or more series. The table below presents our issued and outstanding series of preferred stock as of June 30, 2019 and December 31, 2018. Each series of our outstanding preferred stock has a stated value of $1,000 per share. Further details concerning each series of preferred stock, and the changes in each series during the three-month and six-month periods ending June 30, 2019 and 2018 are discussed in the sections that follow the table.

	June 30, 2019				December 31, 2018
			Carrying				Carrying
	Shares		Value		Shares		Value
Series B Convertible Preferred Stock		100		76,095		100		76,095
Series C Convertible Preferred Stock		-		-		2,150		705,238
Series E Convertible Preferred Stock		-		-		1,200		1,190,000
Series F Convertible Preferred Stock		2,302		1,418,822		-		-
Series G Convertible Preferred Stock		1,000		842,950		-		-
Total		3,402		2,337,867		3,450		1,971,333

Series B Preferred Stock

During the three-month and six-month periods ended June 30, 2019 and 2018, there were no conversions or other transactions involving our Series B Convertible Preferred Stock (“Series B Preferred Stock”). As of June 30, 2019, there are 100 shares of our Series B Convertible Preferred Stock outstanding. The Series B Preferred Stock may be converted at any time at the option of the holder into shares of our common stock at a conversion price of $175 per share.

Series C Preferred Stock

During January and February 2019, 587 shares of our Series C Convertible Preferred Stock (“Series C Preferred Stock”) were converted into 78,280 shares of our common stock. During February 2019, all remaining shares of Series C Preferred Stock (1,563 shares) were exchanged for Series F Preferred Stock. During the three-month and six-month periods ended June 30, 2018, there were no conversions or other transactions involving our Series C Preferred Stock.

Series D Preferred Stock

During the three-month and six-month periods ending June 30, 2018, 345 and 795 shares, respectively, of our Series D Convertible Preferred Stock (“Series D Preferred Stock”) were converted into 46,000 and 106,000 shares, respectively, of our common stock. As of June 30, 2019, there are no shares of our Series D Preferred Stock outstanding.

Series E Preferred Stock

In March 2018, we issued 600 shares of our Series E Convertible Preferred Stock (“Series E Preferred Stock”), for net proceeds of $590,000. In September 2018, we issued an additional 600 shares of Series E Preferred Stock for net proceeds of $600,000. During February 2019, all outstanding shares of Series E Preferred Stock (1,200 shares) were exchanged for Series F Preferred Stock.

Series F Preferred Stock

On February 18, 2019, we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of 2,763 shares of Series F Convertible Preferred Stock (“Series F Preferred Stock”). Each share of Series F Preferred Stock is entitled to a liquidation preference equal to its $1,000 stated value, has no voting rights, and is not entitled to a dividend. The Series F Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) $7.50 per share and (ii) 90% of the volume weighted average price of the common stock immediately preceding the delivery of a notice of conversion. The Series F Preferred Stock contains price adjustment provisions, which may, under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series F Preferred Stock. During the three-month and six-month periods ending June 30, 2019, 281 and 461 shares, respectively, of Series F Preferred Stock were converted into 253,300 and 293,300 shares, respectively, of our common stock. As of June 30, 2019, there are 2,302 shares of our Series F Preferred Stock outstanding.

Series G Preferred Stock

On February 25, 2019, we entered into a Securities Purchase Agreement with the purchasers identified therein (the “Purchasers”) providing for sale to the Purchasers of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock (“Series G Preferred Stock”) and related warrants for gross proceeds of up to $1.0 million, to be funded at up to three different closings. Each share of Series G Preferred Stock is entitled to a liquidation preference equal to its $1,000 stated value, has no voting rights, and is not entitled to a dividend. The Series G Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) $7.50 per share and (ii) 90% of the volume weighted average price of the common stock immediately preceding the delivery of a notice of conversion. The Series G Preferred Stock contains price adjustment provisions, which may, under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series G Preferred Stock.

At the first closing, which occurred on February 26, 2019, we issued 500 shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $250,000 in the aggregate, plus the cancellation of Term Notes held by the Purchasers (see Note 7) in the amount of $250,000. At the first closing we also issued the warrants to purchase an aggregate of 33,334 shares of our common stock. The warrants have an exercise price of $7.50 per share, are exercisable six months from the issuance date, and have a term of exercise equal to five years from the date they first become exercisable. The warrants contain anti-dilution and price adjustment provisions, which may, under certain circumstances reduce the exercise price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then exercise price of the warrants; in the event of such adjustment, the number of shares subject to the warrants will also increase so that the aggregate exercise price remains the same for each warrant. At the second and third closings, which occurred on April 26 and June 19, 2019, we issued an aggregate of 500 additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of $500,000. We also issued the Purchasers warrants to purchase an aggregate of 66,668 shares of our common stock. As of June 30, 2019, there are 1,000 shares of our Series G Preferred Stock outstanding.

10. Common Stock and Stock-Based Compensation

Reverse Stock Split

Following approval by our shareholders at a meeting held on April 15, 2019, on April 30, 2019, we effected a one-for-five hundred reverse split of our common stock by the filing of an amendment to our certificate of incorporation with the State of Delaware. All share and per share information in our condensed consolidated financial statements and notes that relate to our common stock has been retroactively restated to reflect the reverse stock split.

Common Stock Transactions

As discussed in Note 9, during the three-month and six-month periods ended June 30, 2019, we issued 253,300 and 371,580 shares, respectively, of our common stock pursuant to conversions our Series C and Series F Preferred Stock. During the three-month and six-month periods ended June 30, 2018, we issued 46,000 and 106,000 shares, respectively, of our common stock pursuant to conversions our Series D Preferred Stock.

During the three-month and six-month periods ended June 30, 2019, we issued 4,127 shares of our common stock in exchange for consulting services. During the three-month and six-month periods ended June 30, 2018, we issued -0- and 10,000 shares, respectively, of our common stock in exchange for investment banking and financial advisory services. See “Stock-Based Compensation Expense” below.

Stock Options

During the six months ended June 30, 2019, there were no transactions involving our stock option plans. As of June 30, 2019, there are 29,441 stock options outstanding ($53.19/share weighted-average exercise price), 13,585 of which are exercisable at that date ($93.92/share weighted-average exercise price).

Stock Purchase Warrants

During the six months ended June 30, 2019, we issued an aggregate of 100,002 stock purchase warrants in connection with the sale of our Series G Preferred Stock as discussed above. As of June 30, 2019, there are 294,302 stock purchase warrants outstanding ($7.50/share weighted-average exercise price), 194,300 of which are exercisable at that date ($7.50/share weighted-average exercise price).

Stock-Based Compensation Expense

Stock-based compensation expense related to our stock option plans was $26,664 and $53,316 during the three-month and six-month periods ended June 30, 2019, respectively, as compared to $23,221 and $47,199, respectively, during the same periods of 2018. Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of June 30, 2019, there was $157,067 of unrecognized compensation expense related to stock options, which we expect to recognize over a weighted average period of 1.9 years.

During the three-month and six-month periods ended June 30, 2019 we recorded stock-based compensation expense of $78,509 and $205,080, respectively, associated with common stock issued for consulting and financial advisory services, as compared to $57,143 and $85,714, respectively, during the same periods of 2018.

11. Income Taxes

Because of our historically significant net operating losses, we have not paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits will be subject to substantial annual limitations due to ownership change provisions of Section 382 of the Internal Revenue Code. The annual limitation will result in the expiration of net operating losses and credits before utilization.

12. Grants and Collaboration Revenue

We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three-month and six-month periods ended June 30, 2019, we recorded $184,938 and $539,257, respectively, of revenues associated with these grants and contracts, as compared to $93,265 and $309,564, respectively, for the comparable periods of 2018. As of June 30, 2019, there is an aggregate of $2,049,990 in approved grant funds available for use during 2019 and 2020.

During the three-month and six-month periods ended June 30, 2019, we recorded $25,003 and $34,916, respectively, of revenues associated with research collaboration agreements with third parties, as compared to $5,000 for the comparable periods of 2018.

13. Subsequent Events

Stock Transactions

On July 16, 2019, we entered into Exchange Agreements with holders of our Series F and Series G Preferred Stock, pursuant to which the holders exchanged all shares of Series F and Series G Preferred Stock held by them for an aggregate of 3,257 shares of Series H Convertible Preferred Stock (“Series H Preferred Stock”). Each share of Series H Preferred Stock is entitled to a liquidation preference equal to its $1,000 stated value, has no voting rights, and is not entitled to a dividend. The Series H Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) $7.50 per share and (ii) 80% of the lowest volume weighted average price of the common stock during the ten trading days immediately preceding the delivery of a notice of conversion. The Series H Preferred Stock contains price adjustment provisions, which may, under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series F Preferred Stock.

On July 24, 2019, we entered into a Securities Purchase Agreement with the purchasers identified therein (the “Purchasers”) providing for sale to the Purchasers of an aggregate of 700 shares of our Series I Convertible Preferred Stock (“Series I Preferred Stock”) for gross proceeds of $700,000. Each share of Series I Preferred Stock is entitled to a liquidation preference equal to its $1,000 stated value, has no voting rights, and is not entitled to a dividend. The Series I Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) $7.50 per share and (ii) 80% of the lowest volume weighted average price of the common stock during the ten trading days immediately preceding the delivery of a notice of conversion. The Series I Preferred Stock contains price adjustment provisions, which may, under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series I Preferred Stock.

During July and August 2019, holders of our preferred stock converted 46 shares of our Series F Preferred Stock into 88,400 shares of our common stock and 171 shares of our Series H Preferred Stock into 1,737,441 shares of our common stock. During August 2019, we issued 37,827 shares of our common stock in exchange for consulting services.

Item 2 Management’s Discussion and Analysis of Financial Condition And Results of Operations

FORWARD LOOKING STATEMENTS

In addition to historical information, the information included in this Form 10-Q contains forward-looking statements. Forward-looking statements involve numerous risks and uncertainties, including but not limited to the risk factors set forth under the heading “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2018, and should not be relied upon as predictions of future events. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,” ‘‘intends,’’ ‘‘plans,’’ ‘‘pro forma,’’ ‘‘estimates,’’ or ‘‘anticipates’’ or other variations thereof or comparable terminology, or by discussions of strategy, plans, or intentions. Such forward-looking statements are necessarily dependent on assumptions, data, or methods that may be incorrect or imprecise and may be incapable of being realized. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

●	whether we can raise additional capital as and when we need it;

●	whether we are successful in developing our products;

●	whether we are able to obtain regulatory approvals in the United States and other countries for sale of our products;

●	whether we can compete successfully with others in our market; and

●	whether we are adversely affected in our efforts to raise cash by the volatility and disruption of local and national economic, credit and capital markets and the economy in general.

Readers are cautioned not to place undue reliance on forward-looking statements, which reflect our management’s analysis only. We assume no obligation to update forward-looking statements.

Overview

GeoVax is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (Modified Vaccinia Ankara Virus-Like Particle, or “MVA-VLP”). Our recombinant MVA vector expresses target proteins on highly immunogenic VLPs in the person being vaccinated, resulting in durable immune responses while providing the safety characteristics of the replication-defective MVA vector. Important attributes of GeoVax vaccines include single dose, no adjuvant, durable immunity, extensive safety and cost-effective manufacturing.

We have not generated any revenues from the sale of any such products, and we do not expect to generate any such revenues for at least the next several years. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.

Critical Accounting Policies and Estimates

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and adjusts the estimates as necessary. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our financial statements, refer to Item 7 in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 2 to our Consolidated Financial Statements contained in our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no significant changes to our critical accounting policies from those disclosed in our 2018 Annual Report.

Recent Accounting Pronouncements

Information regarding recent accounting pronouncements is contained in Note 3 to the condensed consolidated financial statements, included in this Quarterly Report.

Liquidity and Capital Resources

Our principal uses of cash are to finance our research and development activities. Since inception, we have funded these activities primarily from government grants and clinical trial assistance, and from sales of our equity securities. At June 30, 2019, we had cash and cash equivalents of $216,411 and total assets of $342,633, as compared to $259,701 and $642,064, respectively, at December 31, 2018. At June 30, 2019, we had a working capital deficit of $1,319,179, compared to $1,005,127 at December 31, 2018. Our current liabilities at June 30, 2019 and December 31, 2018 include $1,489,895 and $1,220,179, respectively of accrued management salaries and director fees, payment of which is still being deferred as discussed further below.

Net cash used in operating activities was $773,809 and $761,758 for the six-month periods ended June 30, 2019 and 2018, respectively. Generally, the variances between periods are due to fluctuations in our net losses, offset by non-cash charges such as depreciation and stock-based and deferred compensation expense, and by net changes in our assets and liabilities. Our net losses generally fluctuate based on expenditures for our research activities, partially offset by government grant revenues. As of June 30, 2019, there is $2,049,990 in approved grant funds available for use during 2019 and 2020. Of this amount, we expect that $1,219,066 will be used by us to reimburse third parties who will provide services covered by these grants. See “Results of Operations – Grant and Collaboration Revenues” below for additional details concerning our government grants.

Members of our executive management team and our board of directors have deferred receipt of portions of their salaries and fees in order to help conserve the Company’s cash resources. As of June 30, 2019, the accumulated deferrals totaled $1,489,895. We expect the ongoing deferrals of approximately $34,000 per month for the management salaries and $20-30,000 per quarter for the board of director fees to continue until such time as a significant financing event (as determined by the board of directors) is consummated. The method selected for addressing these accumulated deferrals could have an adverse effect on our liquidity.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has funded the costs of conducting all of our human clinical trials (Phase 1 and Phase 2a) to date for our preventive HIV vaccines, with GeoVax incurring certain costs associated with manufacturing the clinical vaccine supplies and other study support. We expect that NIAID will also fund the cost of a planned Phase 1 trial (HVTN 132), conducted by the HIV Trials Network (HVTN), to further evaluate the safety and immunogenicity of adding “protein boost” components to our vaccine, GOVX-B11. The timing of HVTN 132 is uncertain, and dependent upon components other than our vaccine, but we expect the HVTN to commence patient enrollment in 2020. Additionally, we are party to a collaboration with American Gene Technologies International, Inc. (AGT) whereby AGT intends to conduct a Phase 1 human clinical trial with our combined technologies, with the ultimate goal of developing a functional cure for HIV infection. We expect that AGT will begin the Phase 1 trial in late 2019. We are also currently in discussions with a public-private consortium for the use of our vaccine in a similar effort toward developing a cure for HIV infection; we expect these studies may begin in early 2020.

Net cash used in investing activities was $4,272 and $-0- for the six-month periods ended June 30, 2019 and 2018, respectively. Our investing activities have consisted predominantly of capital expenditures.

Net cash provided by financing activities was $734,791 and $640,000 for the six-month periods ended June 30, 2019 and 2018, respectively. Net cash provided by financing activities during the 2018 period relates to the sale by us of shares of our Series E convertible preferred stock ($590,000) and our issuance of a five-year Senior Promissory Note (the “GRA Note”) to the Georgia Research Alliance, Inc. for $50,000. The GRA Note bears an annual interest rate of 5%, payable monthly, with principal repayments which began in March 2019. Net cash provided by financing activities during the 2019 period relates to the sale by us of shares of our Series G convertible preferred stock for net proceeds of $740,000 (see discussion below) and $5,209 in repayments toward the GRA Note.

On February 25, 2019, we entered into a Securities Purchase Agreement with the purchasers identified therein (the “Purchasers”) providing for sale to the Purchasers of an aggregate of up to 1,000 shares of our Series G Convertible Preferred Stock (“Series G Preferred Stock”) and related warrants for gross proceeds of up to $1.0 million, to be funded at up to three different closings. At the first closing, which occurred on February 26, 2019, we issued 500 shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $250,000 in the aggregate ($240,000 after deducting certain expenses of the Purchasers), plus the cancellation of Term Notes held by the Purchasers in the amount of $250,000. At the first closing we also issued the Purchasers warrants to purchase an aggregate of 33,334 shares of our common stock. At the second closing, which occurred on April 26, 2019, we issued an additional 250 shares of Series G Preferred Stock in exchange for the payment by the Purchasers of $250,000 in the aggregate. At the second and third closings, which occurred on April 26 and June 19, 2019, we issued an aggregate of 500 additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of $500,000. We also issued the Purchasers warrants to purchase an aggregate of 66,668 shares of our common stock.

On April 15, 2019, our stockholders approved, and on April 30, 2019 we implemented, a one-for-five hundred reverse split of our common stock, which is intended to not only improve the marketability of our stock, but also to provide additional shares of authorized common stock available to meet our equity financing needs. The reverse stock split is also intended to help us meet the minimum price requirements for listing our common stock on the Nasdaq Capital Market, should that be a condition to completing any of the financing options we may contemplate. The reverse stock split ratio was chosen in part to support a higher stock price per share than the lower ratios in the range approved by our stockholders. There can be no assurance the necessary minimum price requirements will be met.

As of June 30, 2019, we had an accumulated deficit of approximately $41.8 million, and we expect the amount of the accumulated deficit will continue to increase, as it will be expensive to continue our research and development efforts. We have received a “going concern” opinion from our independent registered public accountants reflecting substantial doubt about our ability to continue as a going concern. We believe that our existing cash resources (including funds received from the July financing discussed above), combined with funding from existing government grants and clinical trial support, will be sufficient to fund our planned operations into the first quarter of 2020. We will require additional funds to continue our planned operations beyond that date. We are currently seeking sources of capital through additional government grant programs and clinical trial support, and we plan to conduct additional offerings of our equity securities. Additional funding may not be available on favorable terms or at all and if we fail to obtain additional capital when needed, we may be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that are likely or reasonably likely to have a material effect on our financial condition or results of operations.

Contractual Obligations

The table below summarizes our contractual obligations as of June 30, 2019, aggregated by type (in thousands). Our contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude contingent liabilities for which we cannot reasonably predict future payment. Additionally, the expected timing of payment of the obligations presented below is estimated based on current information. Timing of payments and actual amounts paid may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations.

	Payments Due by Period
Contractual Obligations	Total		Less than 1 Year		1-3 Years		4-5 Years		More than 5 years
Operating Lease Obligations ⁽¹⁾	$	81	$	81	$	--	$	--	$	--
Purchase Obligations ⁽²⁾		459		459		--		--		--
Total	$	540	$	540	$	--	$	--	$	--

(1)

Our operating lease obligations relate to the facility lease for our 8,430 square foot facility in Smyrna, Georgia, which houses our laboratory operations and our administrative offices. The current term of our lease expires on December 31, 2019. We have annual extension options through December 31, 2022 which have not yet been exercised by us and may be cancellable by our landlord.

(2)

Purchase obligations relate to contracts for research activities, payment of which will be reimbursable to us pursuant to our government grants.

As of June 30, 2019, except as disclosed in the table above, we had no other material firm purchase obligations or commitments for capital expenditures and no committed lines of credit or other committed funding or long-term debt, with the exception of the note payable to GRA ($44,791 remaining principal balance at June 30, 2019). We have employment agreements with our executive officers, each of which may be terminated with no more than 90 days’ advance written notice. Pursuant to existing technology license agreements, we may be required to make potential future milestone and royalty payments which are contingent upon the occurrence of future events. Such events include development milestones, regulatory approvals and product sales. Because the achievement of these milestones is currently neither probable nor reasonably estimable, the contingent payments have not been included in the table above or recorded in our financial statements.

Results of Operations

Net Loss

We recorded a net loss of $654,148 for the three-month period ended June 30, 2019, as compared to $637,043 for the three-month period ended June 30, 2018. For the six-month period ended June 30, 2019, we recorded a net loss of $1,355,602, as compared to $1,258,856 for the six-month period ended June 30, 2018. Our net losses will typically fluctuate due to the timing of activities and related costs associated with our vaccine research and development activities and our general and administrative costs, as described in more detail below.

Grant and Collaboration Revenues

During the three-month and six-month periods ended June 30, 2019, we recorded grant and collaboration revenues of $209,941 and $574,173, respectively, as compared to $93,265 and $314,564, respectively, during the comparable periods of 2018.

Grant Revenues – Our grant revenues relate to grants and contracts from agencies of the U.S. government in support of our vaccine development activities. We record revenue associated with these grants as the related costs and expenses are incurred. The difference in our grant revenues from period to period is dependent upon our expenditures for activities supported by the grants and fluctuates based on the timing of the expenditures. Additional detail concerning our grant revenues and the remaining funds available for use as of June 30, 2019 is presented in the table below.

	Grant Revenues Recorded During the Periods:								Unused Funds
	Three Months Ended June 30,				Six Months Ended June 30,				Available at
	2019		2018		2019		2018		June 30, 2019
Lassa Fever – U.S. Army Grant		151,819		-		294,504		-		1,985,240
Lassa Fever – SBIR Grant		18,625		32,234		82,292		32,234		64,750
Zika – SBIR Grant		14,494		25,346		162,461		54,134		-
HIV – SBIR Grant	$	-	$	35,685	$	-	$	223,196	$	-
Total	$	184,938	$	93,265	$	539,257	$	309,564	$	2,049,990

Collaboration Revenues – In addition to the grant revenues above, during the three-month and six-month periods ended June 30, 2019 we recorded revenues associated with several research collaborations with third parties of $25,003 and $34,916, respectively, as compared to $-0- and $5,000, respectively, during the comparable periods of 2018. These amounts primarily represent amounts paid to us by the other parties for materials and other costs associated with joint studies.

Research and Development Expenses

Our research and development expenses were $451,227 and $1,006,945 for the three-month and six-month periods ended June 30, 2019 as compared to $372,202 and $859,196 for the comparable periods of 2018. Research and development expense for the three-month and six-month periods of 2019 includes stock-based compensation expense of $11,322 and $22,641 respectively, as compared to $10,511 and $21,462, respectively, for the comparable periods of 2018 (see discussion under “Stock-Based Compensation Expense” below).

Our research and development expenses can fluctuate considerably on a period-to-period basis, depending on our need for vaccine manufacturing by third parties, the timing of expenditures related to our government grants, the timing of costs associated with any clinical trials being funding directly by us, and other factors. Research and development expenses increased by $147,749, or 17%, from the six-month period of 2018 to 2019 primarily due to the timing of expenditures related to our government grants. Our research and development costs do not include costs incurred by the HIV Vaccine Trials Network (HVTN) in conducting clinical trials of our preventive HIV vaccines; those costs are funded directly to the HVTN by NIAID.

We do not disclose our research and development expenses by project, since our employees’ time is spread across multiple programs and our laboratory facility is used for multiple development projects. We track the direct cost of research and development expenses related to government grant revenue by the percentage of assigned employees’ time spent on each grant and other direct costs associated with each grant. Indirect costs associated with grants are not tracked separately but are applied based on a contracted overhead rate negotiated with the NIH. Therefore, the recorded revenues associated with government grants approximates the costs incurred.

We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with vaccine development. Due to these uncertainties, our future expenditures are likely to be highly volatile in future periods depending on the outcomes of the trials and studies. As we obtain data from pre-clinical studies and clinical trials, we may elect to discontinue or delay vaccine development programs to focus our resources on more promising vaccine candidates. Completion of preclinical studies and human clinical trials may take several years or more, but the length of time can vary substantially depending upon several factors. The duration and the cost of future clinical trials may vary significantly over the life of the project because of differences arising during development of the human clinical trial protocols, including the number of patients that ultimately participate in the clinical trial; the duration of patient follow-up that seems appropriate in view of the results; the number of clinical sites included in the clinical trials; and the length of time required to enroll suitable patient subjects.

General and Administrative Expenses

Our general and administrative expenses were $412,650 and $922,714 for the three-month and six-month periods ended June 30, 2019, as compared to $359,197 and $716,425 during the comparable periods of 2018. General and administrative costs include officers’ salaries, legal and accounting costs, patent costs, and other general corporate expenses. General and administrative expense for the three-month and six-month periods of 2019 include stock-based compensation expense of $93,851and $235,755, respectively; as compared to $69,853 and $111,451, respectively, for the comparable periods of 2018 (see discussion under “Stock-Based Compensation Expense” below). Excluding stock-based compensation expense, general and administrative expenses were $318,799 and $686,959 during the three-month and six-month periods ended June 30, 2019, respectively, as compared to $289,344 and $604,974, respectively during the comparable periods of 2018. The overall increase in general and administrative expense from 2018 to 2019 is primarily attributable to higher legal fees, insurance costs, and costs associated with the conduct of a special meeting of stockholders. We expect that our general and administrative costs may increase in the future in support of expanded research and development activities and other general corporate activities.

Stock-Based Compensation Expense

For the three-month and six-month periods ended June 30, 2019 and 2018, the components of stock-based compensation expense were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Stock option expense	$	26,664	$	23,221	$	53,316	$	47,199
Stock issued for services		78,509		57,143		205,080		85,714
Total stock-based compensation expense	$	105,173	$	80,364	$	258,396	$	132,913

In general, stock-based compensation expense is allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, consultant or director to whom the stock compensation was granted. For the three-month and six-month periods ended June 30, 2019 and 2018, stock-based compensation expense was allocated as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Expense Allocated to:	2019		2018		2019		2018
General and administrative expense	$	93,851	$	69,853	$	235,755	$	111,451
Research and development expense		11,322		10,511		22,641		21,462
Total stock-based compensation expense	$	105,173	$	80,364	$	258,396	$	132,913

Other Income (Expense)

Interest income for the three-month and six-month periods ended June 30, 2019 was $881 and $2,105, respectively, as compared to $1,716 and $3,034, respectively, for comparable periods of 2018. The variances between periods are primarily attributable to cash available for investment and interest rate fluctuations. Interest expense for the three-month and six-month periods ended June 30, 2019 was $1,093 and $2,221, respectively, as compared to $625 and $833, respectively, for comparable periods of 2018. Interest expense relates to the GRA Note and financing costs associated with insurance premiums.

Item 3 Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4 Controls and Procedures

Evaluation of disclosure controls and procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that the information required to be disclosed in reports filed or submitted under the Securities Exchange Act of 1934, as amended (Exchange Act), is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to management, including the Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

Our management has carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial and Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15 and 15d-15 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Changes in internal control over financial reporting

There was no change in our internal control over financial reporting that occurred during the three months ended June 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

PART II -- OTHER INFORMATION

Item 1

Legal Proceedings

None.

Item 1A

Risk Factors

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A.

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds

None not previously disclosed on Form 8-K.

Item 3

Defaults Upon Senior Securities

None.

Item 4

Mine Safety Disclosures

Not applicable

Item 5

Other Information

None.

Item 6

Exhibits

Exhibit
Number	Description

3.1	Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 30, 2019 (1)
4.1	Form of Stock Certificate to be issued after April 30, 2019 to represent the Company’s Common Stock, par value $0.001 (1)
4.2.1	Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (2)
4.2.2	Form of Stock Certificate for the Series F Convertible Preferred Stock (2)
4.3.1	Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (3)
4.3.2	Form of Stock Certificate for the Series G Convertible Preferred Stock (3)
4.4.1	Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Preferred Stock (4)
4.4.2	Form of Stock Certificate for the Series H Convertible Preferred Stock (4)
4.5.1	Certificate of Designation of Preferences, Rights and Limitations of Series I Convertible Preferred Stock (5)
4.5.2	Form of Stock Certificate for the Series I Convertible Preferred Stock (5)
10.1	Form of Exchange Agreement, dated February 18, 2019 (2)
10.2	Form of Securities Purchase Agreement dated February 25, 2019 (3)
10.3	Form of Series I Common Stock Purchase Warrant (3)
10.4	Form of Exchange Agreement, dated July 16, 2019 (4)
10.5	Form of Securities Purchase Agreement dated July 24, 2019 (5)
31.1*	Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934
31.2*	Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934
32.1*	Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002

101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document

_____________________

*	Filed herewith

XBRL (Extensible Business Reporting Language) information furnished hereto are deemed not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

(1)	Incorporated by reference from the registrant’s Current Report on Form 8-K filed April 30, 2019.
(2)	Incorporated by reference from the registrant’s Current Report on Form 8-K filed February 19, 2019.
(3)	Incorporated by reference from the registrant’s Current Report on Form 8-K filed February 26, 2019.
(4)	Incorporated by reference from the registrant’s Current Report on Form 8-K filed July 17, 2019.
(5)	Incorporated by reference from the registrant’s Current Report on Form 8-K filed July 24, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

	GEOVAX LABS, INC. (Registrant)


Date: August 13, 2019	By: /s/ Mark W. Reynolds
	Mark W. Reynolds Chief Financial Officer (duly authorized officer and principal financial officer)

EX-31.1 2 ex_153740.htm EXHIBIT 31.1 ex_153740.htm

Exhibit 31.1

CERTIFICATION

PURSUANT TO RULE 13a-14(a) or 15d-14(a)

OF THE

SECURITIES EXCHANGE ACT OF 1934

I, David A. Dodd, President and Chief Executive Officer of GeoVax Labs, Inc. certify that:

(1)

I have reviewed this quarterly report on Form 10-Q of GeoVax Labs, Inc.;

(2)

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 13, 2019

/s/ David A. Dodd

David A. Dodd

President & Chief Executive Officer

EX-31.2 3 ex_153741.htm EXHIBIT 31.2 ex_153741.htm

Exhibit 31.2

CERTIFICATION

PURSUANT TO RULE 13a-14(a) or 15d-14(a)

OF THE

SECURITIES EXCHANGE ACT OF 1934

I, Mark W. Reynolds, Chief Financial Officer of GeoVax Labs, Inc. certify that:

(1)

I have reviewed this quarterly report on Form 10-Q of GeoVax Labs, Inc.;

(2)

(3)

(4)

(5)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 13, 2019

/s/ Mark W. Reynolds

Mark W. Reynolds

Chief Financial Officer

EX-32.1 4 ex_153742.htm EXHIBIT 32.1 ex_153742.htm

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of GeoVax Labs, Inc. (the "Company") on Form 10-Q for the three months ended June 30, 2019, I, David A. Dodd, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that to the best of my knowledge:

1. The quarterly report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2019

/s/ David A. Dodd

David A. Dodd

President & Chief Executive Officer

EX-32.2 5 ex_153743.htm EXHIBIT 32.2 ex_153743.htm

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of GeoVax Labs, Inc. (the "Company") on Form 10-Q for the three months ended June 30, 2019, I, Mark W. Reynolds, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that to the best of my knowledge:

1. The quarterly report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2. The information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2019

/s/ Mark W. Reynolds

Mark W. Reynolds

Chief Financial Officer

EX-101.INS 6 govx-20190630.xml XBRL INSTANCE DOCUMENT false --12-31 Q2 2019 2019-06-30 10-Q 0000832489 2477584 Yes false Non-accelerated Filer GeoVax Labs, Inc. false true Common Stock govx 361470 295670 194300 7.50 100002 7.50 1000 500 33334 500 500 175 7.50 7.50 7.50 7.50 0.9 0.9 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div>     Grants and Collaboration Revenue</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>we recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$184,938</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$539,257,</div> respectively, of revenues associated with these grants and contracts, as compared to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$93,265</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$309,564,</div> respectively, for the comparable periods of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there is an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,049,990</div> in approved grant funds available for use during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>we recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,003</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$34,916,</div> respectively, of revenues associated with research collaboration agreements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties, as compared to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,000</div> for the comparable periods of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div></div> 2763 1000000 250000 500000 500000 590000 600000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48.9%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76,095</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series C Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,150</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">705,238</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series E Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,190,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series F Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,302</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,418,822</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series G Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,402</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,337,867</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,971,333</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 402 78509 205080 57143 85714 2049990

116207

125859

1510268

1238552

1128425

924509

667041

663246

38165172

37482766

26652

26664

23978

23221

581793

497098

26664

53316

23221

47199

376130

351684

51270

51155

8400

342633

642064

319796

619704

259701

312727

216411

190969

-43290

-121758

7.50

66668

294302

0.001

600000000

813916

437807

813916

437807

814

438

1563

1200

587

461

795

587

1563

345

795

1200

281

253300

293300

171

2763

78280

293300

106000

78280

46000

106000

253300

371580

3257

88400

1737441

250

250000

0.05

P5Y

11010

3795

9930

-1.01

-2.05

-2.37

-4.50

157067

P1Y328D

412650

359197

922714

716425

64246

121814

262064

252802

-41695

-57568

-59758

586

1207

625

833

1093

625

2221

833

881

1716

2105

3034

40316

80633

39136

78273

80633

P1Y

1671266

1664411

342633

642064

1638975

1624831

2083

12500

6250

32291

39580

734791

640000

-4272

-773809

-761758

-1355602

-1258856

-654148

-637043

-701454

-654148

-621813

-637043

-212

1091

-116

2201

12500

260420

863877

731399

1929659

1575621

-653936

-638134

-1355486

-1261057

20373

18373

4272

0.01

1000

10000000

3402

3450

3402

3450

100

2302

1000

100

2150

1200

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div>     Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Prefer</div><div style="display: inline; font-style: italic;">red Stock</div><div style="display: inline; font-style: italic;"> Summary</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are authorized to issue up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000,000</div> shares of our Preferred Stock, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$.01</div> par value, which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more series. The table below presents our issued and outstanding series of preferred stock as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div>Each series of our outstanding preferred stock has a stated value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div></div></div></div></div> per share. Further details concerning each series of preferred stock, and the changes in each series during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> are discussed in the sections that follow the table.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="border-bottom: 1px none rgb(0, 0, 0); text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Carrying</div> </td> <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48.9%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series B Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76,095</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series C Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,150</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">705,238</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series E Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,190,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series F Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,302</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,418,822</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series G Convertible Preferred Stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,402</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,337,867</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,971,333</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Series B Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div></div></div> conversions or other transactions involving our Series B Convertible Preferred Stock (“Series B Preferred Stock”). As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div> shares of our Series B Convertible Preferred Stock outstanding. The Series B Preferred Stock <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be converted at any time at the option of the holder into shares of our common stock at a conversion price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$175</div> per share.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Series </div><div style="display: inline; font-style: italic;">C</div><div style="display: inline; font-style: italic;"> Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2019, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">587</div> shares of our Series C Convertible Preferred Stock (“Series C Preferred Stock”) were converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78,280</div> shares of our common stock. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2019, </div>all remaining shares of Series C Preferred Stock (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,563</div> shares) were exchanged for Series F Preferred Stock. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div></div> conversions or other transactions involving our Series C Preferred Stock.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Series </div><div style="display: inline; font-style: italic;">D</div><div style="display: inline; font-style: italic;"> Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">345</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">795</div> shares, respectively, of our Series D Convertible Preferred Stock (“Series D Preferred Stock”) were converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106,000</div> shares, respectively, of our common stock. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> shares of our Series D Preferred Stock outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Series </div><div style="display: inline; font-style: italic;">E</div><div style="display: inline; font-style: italic;"> Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2018, </div>we issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">600</div> shares of our Series E Convertible Preferred Stock (“Series E Preferred Stock”), for net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$590,000.</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2018, </div>we issued an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">600</div> shares of Series E Preferred Stock for net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$600,000.</div> During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2019, </div>all outstanding shares of Series E Preferred Stock (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,200</div> shares) were exchanged for Series F Preferred Stock.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Series F Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 18, 2019, </div>we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,763</div> shares of Series F Convertible Preferred Stock (“Series F Preferred Stock”). Each share of Series F Preferred Stock is entitled to a liquidation preference equal to its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> stated value, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights, and is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> entitled to a dividend. The Series F Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.50</div> per share and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90%</div> of the volume weighted average price of the common stock immediately preceding the delivery of a notice of conversion. The Series F Preferred Stock contains price adjustment provisions, which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series F Preferred Stock. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">281</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">461</div> shares, respectively, of Series F Preferred Stock were converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">253,300</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293,300</div> shares, respectively, of our common stock. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,302</div> shares of our Series F Preferred Stock outstanding.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Series G Preferred Stock</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 25, 2019, </div>we entered into a Securities Purchase Agreement with the purchasers identified therein (the “Purchasers”) providing for sale to the Purchasers of an aggregate of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div> shares of our Series G Convertible Preferred Stock (“Series G Preferred Stock”) and related warrants for gross proceeds of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million, to be funded at up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> different closings. Each share of Series G Preferred Stock is entitled to a liquidation preference equal to its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> stated value, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights, and is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> entitled to a dividend. The Series G Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.50</div> per share and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90%</div> of the volume weighted average price of the common stock immediately preceding the delivery of a notice of conversion. The Series G Preferred Stock contains price adjustment provisions, which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series G Preferred Stock.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> closing, which occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 26, 2019, </div>we issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div> shares of Series G Preferred Stock in exchange for the payment by the Purchasers of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000</div> in the aggregate, plus the cancellation of Term Notes held by the Purchasers (see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div>) in the amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$250,000.</div> At the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> closing we also issued the warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,334</div> shares of our common stock. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.50</div> per share, are exercisable <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months from the issuance date, and have a term of exercise equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years from the date they <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> become exercisable. The warrants contain anti-dilution and price adjustment provisions, which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>under certain circumstances reduce the exercise price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then exercise price of the warrants; in the event of such adjustment, the number of shares subject to the warrants will also increase so that the aggregate exercise price remains the same for each warrant. At the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> closings, which occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 26 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 19, 2019, </div>we issued an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500</div></div> additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div>.</div> We also issued the Purchasers warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66,668</div> shares of our common stock. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div> shares of our Series G Preferred Stock outstanding.</div></div>

2337867

1971333

76095

705238

1190000

1418822

842950

39139

238189

740000

590000

700000

50000

534578

530306

115605

28685

678868

674596

11827

11350

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">June 30,</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Laboratory equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">534,578</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">530,306</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">115,605</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">115,605</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other furniture, fixtures & equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Total property and equipment</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">678,868</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674,596</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Accumulated depreciation and amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(667,041</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(663,246</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,827</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,350</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

5209

451227

372202

1006945

859196

-41832486

-40476884

184938

539257

93265

309564

25003

34916

5000

209941

93265

574173

314564

258396

132913

13585

93.92

29441

53.19

3450

437807

3183

556489

3402

813916

3670

213474

3820

283474

3475

329474

-767

118280

-281

253300

-450

60000

-345

46000

4127

10000

4127

37827

4127

10000

600

700

500

600

-303475

118

303357

-172941

254

172687

-441000

440940

-338100

338054

5996

6000

199990

200000

404250

85750

490000

438700

61300

500000

590000

-1328633

-1022347

1971333

438

37482766

-40476884

2072108

556

37898525

-41178338

-1207149

2337867

814

38165172

-41832486

1899085

213

35696435

-37916790

-321057

2048085

283

36361343

-38538603

-128892

1709985

329

36722618

-39175646

-742714

500

459000

P5Y

649486

310419

571032

279551

xbrli:shares xbrli:pure utr:sqft iso4217:USD iso4217:USD xbrli:shares 0000832489 2018-01-01 2018-03-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000832489 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000832489 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0000832489 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000832489 2018-01-01 2018-06-30 0000832489 govx:ConversionFromSeriesDConvertiblePreferredStockToCommonStockMember 2018-01-01 2018-06-30 0000832489 govx:ConversionOfSeriesDPreferredStockIntoCommonStockMember 2018-01-01 2018-06-30 0000832489 govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember 2018-01-01 2018-06-30 0000832489 us-gaap:SeniorNotesMember 2018-01-01 2018-06-30 0000832489 govx:NIHGrantsMember 2018-01-01 2018-06-30 0000832489 govx:ResearchAgreementsMember 2018-01-01 2018-06-30 0000832489 govx:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-06-30 0000832489 govx:SeriesCConvertiblePreferredStockMember 2018-01-01 2018-06-30 0000832489 us-gaap:SeniorNotesMember 2018-02-28 2018-02-28 0000832489 govx:SeriesEConvertiblePreferredStockMember 2018-03-01 2018-03-31 0000832489 2018-04-01 2018-06-30 0000832489 govx:ConversionOfSeriesDPreferredStockIntoCommonStockMember 2018-04-01 2018-06-30 0000832489 govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember 2018-04-01 2018-06-30 0000832489 us-gaap:SeniorNotesMember 2018-04-01 2018-06-30 0000832489 govx:NIHGrantsMember 2018-04-01 2018-06-30 0000832489 govx:ResearchAgreementsMember 2018-04-01 2018-06-30 0000832489 govx:SeriesBConvertiblePreferredStockMember 2018-04-01 2018-06-30 0000832489 govx:SeriesCConvertiblePreferredStockMember 2018-04-01 2018-06-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000832489 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000832489 us-gaap:PreferredStockMember 2018-04-01 2018-06-30 0000832489 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000832489 govx:SeriesEConvertiblePreferredStockMember 2018-09-01 2018-09-30 0000832489 govx:ConversionOfSeriesCPreferredStockIntoCommonStockMember 2019-01-01 2019-02-28 0000832489 2019-01-01 2019-03-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000832489 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000832489 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0000832489 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000832489 2019-01-01 2019-06-30 0000832489 govx:CommonStockPurchaseWarrantsMember 2019-01-01 2019-06-30 0000832489 govx:ConversionFromSeriesCAndFConvertiblePreferredStockToCommonStockMember 2019-01-01 2019-06-30 0000832489 govx:ConversionOfSeriesCAndSeriesEPreferredStockIntoSeriesFPreferredStockMember 2019-01-01 2019-06-30 0000832489 govx:ConversionOfSeriesCPreferredStockIntoCommonStockMember 2019-01-01 2019-06-30 0000832489 govx:ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember 2019-01-01 2019-06-30 0000832489 govx:ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember 2019-01-01 2019-06-30 0000832489 govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember 2019-01-01 2019-06-30 0000832489 govx:SeriesGConvertiblePreferredStockIssuedInExchangeForCancellationOfTermNotesPayableMember 2019-01-01 2019-06-30 0000832489 us-gaap:SeniorNotesMember 2019-01-01 2019-06-30 0000832489 govx:NIHGrantsMember 2019-01-01 2019-06-30 0000832489 govx:ResearchAgreementsMember 2019-01-01 2019-06-30 0000832489 govx:SeriesBConvertiblePreferredStockMember 2019-01-01 2019-06-30 0000832489 govx:ConversionOfSeriesCPreferredStockIntoSeriesFPreferredStockMember 2019-02-01 2019-02-28 0000832489 govx:ConversionOfSeriesEPreferredStockIntoSeriesFPreferredStockMember 2019-02-01 2019-02-28 0000832489 govx:SeriesFConvertiblePreferredStockMember 2019-02-18 2019-02-18 0000832489 govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember 2019-02-25 2019-02-25 0000832489 govx:SeriesIWarrantsMember 2019-02-26 2019-02-26 0000832489 govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember 2019-02-26 2019-02-26 0000832489 2019-04-01 2019-06-30 0000832489 govx:ConversionFromSeriesCAndFConvertiblePreferredStockToCommonStockMember 2019-04-01 2019-06-30 0000832489 govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember 2019-04-01 2019-06-30 0000832489 us-gaap:SeniorNotesMember 2019-04-01 2019-06-30 0000832489 govx:NIHGrantsMember 2019-04-01 2019-06-30 0000832489 govx:ResearchAgreementsMember 2019-04-01 2019-06-30 0000832489 govx:SeriesBConvertiblePreferredStockMember 2019-04-01 2019-06-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000832489 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000832489 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0000832489 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000832489 govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember 2019-04-26 2019-04-26 0000832489 govx:ReverseStockSplitMember 2019-04-30 2019-04-30 0000832489 govx:SeriesGConvertiblePreferredStockAndRelatedWarrantsMember 2019-06-19 2019-06-19 0000832489 govx:ConversionOfSeriesFPreferredStockIntoCommonStockMember us-gaap:SubsequentEventMember 2019-07-01 2019-07-31 0000832489 govx:ConversionFromSeriesFAndSeriesGPreferredStockToSeriesHPreferredStockMember us-gaap:SubsequentEventMember 2019-07-16 2019-07-16 0000832489 govx:SeriesIConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2019-07-24 2019-07-24 0000832489 govx:ConversionOfSeriesHPreferredStockIntoCommonStockMember us-gaap:SubsequentEventMember 2019-08-01 2019-08-12 0000832489 us-gaap:SubsequentEventMember 2019-08-01 2019-08-12 0000832489 2017-12-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000832489 us-gaap:CommonStockMember 2017-12-31 0000832489 us-gaap:PreferredStockMember 2017-12-31 0000832489 us-gaap:RetainedEarningsMember 2017-12-31 0000832489 us-gaap:SeniorNotesMember 2018-02-28 0000832489 2018-03-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000832489 us-gaap:CommonStockMember 2018-03-31 0000832489 us-gaap:PreferredStockMember 2018-03-31 0000832489 us-gaap:RetainedEarningsMember 2018-03-31 0000832489 2018-06-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000832489 us-gaap:CommonStockMember 2018-06-30 0000832489 us-gaap:PreferredStockMember 2018-06-30 0000832489 us-gaap:RetainedEarningsMember 2018-06-30 0000832489 govx:TermNotesMember 2018-12-27 0000832489 2018-12-31 0000832489 govx:LaboratoryEquipmentMember 2018-12-31 0000832489 us-gaap:LeaseholdImprovementsMember 2018-12-31 0000832489 govx:OtherFurnitureFixturesAndEquipmentMember 2018-12-31 0000832489 govx:SeriesBConvertiblePreferredStockMember 2018-12-31 0000832489 govx:SeriesCConvertiblePreferredStockMember 2018-12-31 0000832489 govx:SeriesEConvertiblePreferredStockMember 2018-12-31 0000832489 govx:SeriesFConvertiblePreferredStockMember 2018-12-31 0000832489 govx:SeriesGConvertiblePreferredStockMember 2018-12-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000832489 us-gaap:CommonStockMember 2018-12-31 0000832489 us-gaap:PreferredStockMember 2018-12-31 0000832489 us-gaap:RetainedEarningsMember 2018-12-31 0000832489 govx:SeriesFConvertiblePreferredStockMember 2019-02-18 0000832489 govx:SeriesGConvertiblePreferredStockMember 2019-02-25 0000832489 govx:SeriesGWarrantsMember 2019-02-26 0000832489 govx:SeriesIWarrantsMember 2019-02-26 0000832489 2019-03-31 0000832489 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000832489 us-gaap:CommonStockMember 2019-03-31 0000832489 us-gaap:PreferredStockMember 2019-03-31 0000832489 us-gaap:RetainedEarningsMember 2019-03-31 0000832489 2019-06-30 0000832489 govx:CommonStockPurchaseWarrantsMember 2019-06-30 0000832489 us-gaap:SeniorNotesMember 2019-06-30 0000832489 govx:NIHGrantsMember 2019-06-30 0000832489 govx:LaboratoryEquipmentMember 2019-06-30 0000832489 us-gaap:LeaseholdImprovementsMember 2019-06-30 0000832489 govx:OtherFurnitureFixturesAndEquipmentMember 2019-06-30 0000832489 govx:SeriesBConvertiblePreferredStockMember 2019-06-30 0000832489 govx:SeriesCConvertiblePreferredStockMember 2019-06-30 0000832489 govx:SeriesDConvertiblePreferredStockMember 2019-06-30 0000832489 govx:SeriesEConvertiblePreferredStockMember 2019-06-30 0000832489 govx:SeriesFConvertiblePreferredStockMember 2019-06-30 0000832489 govx:SeriesGConvertiblePreferredStockMember 2019-06-30 0000832489 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000832489 us-gaap:CommonStockMember 2019-06-30 0000832489 us-gaap:PreferredStockMember 2019-06-30 0000832489 us-gaap:RetainedEarningsMember 2019-06-30 0000832489 govx:SeriesHConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2019-07-16 0000832489 govx:SeriesIConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2019-07-24 0000832489 2019-08-13

EX-101.SCH 7 govx-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Description of Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Notes Payable link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Commitments link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Preferred Stock link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Common Stock and Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Grants and Collaboration Revenue link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 6 - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 9 - Preferred Stock (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Basis of Presentation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 8 - Commitments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Preferred Stock (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 9 - Preferred Stock - Preferred Stock Summary (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 10 - Common Stock and Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 12 - Grants and Collaboration Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 13 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 govx-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 govx-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 govx-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Other income (expense): Note To Financial Statement Details Textual Note 5 - Property and Equipment Note 6 - Accrued Expenses Note 9 - Preferred Stock Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Grant funds and other receivables Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) Schedule of Preferred Stock [Table Text Block] Tabular disclosure of preferred stock. Note 9 - Preferred Stock - Preferred Stock Summary (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Income Tax Disclosure [Text Block] us-gaap_ShareBasedCompensation Stock-based compensation expense Convertible note, shares issued (in shares) us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year us-gaap_LiabilitiesCurrent Total current liabilities Convertible note, value Debt Conversion Description [Axis] Debt Conversion, Name [Domain] Operating expenses: Series H Convertible Preferred Stock [Member] Information pertaining to Series H Convertible Preferred Stock. Series I Convertible Preferred Stock [Member] Information pertaining to Series I Convertible Preferred Stock. us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term Conversion of Series H Preferred Stock Into Common Stock [Member] Represents information about conversion of series H preferred stock into common stock. Conversion from Series F and Series G Preferred Stock to Series H Preferred Stock [Member] Informatio pertaining to the conversion from Series F and Series G Preferred Stock to Series H Preferred Stock. Series C Convertible Preferred Stock [Member] Represents series C convertible stock as per the securities purchase agreement. Conversion of stock, shares issued (in shares) Conversion of Stock, Shares Issued us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Depreciation and amortization Convertible preferred stock (in shares) Conversion of Stock, Shares Converted us-gaap_SharesIssued Balance (in shares) Balance (in shares) Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price us-gaap_AssetsCurrent Total current assets Current portion of notes payable (Note 7) Stockholders' Equity Note Disclosure [Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 813,916 and 437,807 at June 30, 2019 and December 31, 2018, respectively Senior Notes [Member] Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Accrued expenses (Note 6) Total accrued expenses Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Product and Service [Axis] Product and Service [Domain] Preferred Stock, $.01 par value: Authorized shares – 10,000,000 Issued and outstanding shares – 3,402 and 3,450 at June 30, 2019 and December 31, 2018, respectively (Note 9) Preferred Stock Other accrued expenses Preferred stock, shares issued (in shares) Accrued management salaries us-gaap_PolicyTextBlockAbstract Accounting Policies Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Grant and collaboration revenue Revenue from Contract with Customer, Including Assessed Tax us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Series G Warrants [Member] Represents the information pertaining to the Series G Warrants. Laboratory Equipment [Member] Other Furniture Fixtures And Equipment [Member] Government Grants and Contracts [Text Block] Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. Current liabilities: NIH Grants [Member] Grants from the National Institutes of Health (NIH). Deposits us-gaap_Assets Total assets Preferred Stock [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Cash flows from operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Commitments Disclosure [Text Block] Statement [Line Items] Additional paid-in capital Stockholders’ equity (deficiency): Leasehold Improvements [Member] Conversion From Series D Convertible Preferred Stock To Common Stock [Member] The conversion of Series D convertible preferred stock to common stock. Property, Plant and Equipment, Type [Axis] us-gaap_NonoperatingIncomeExpense Total other income (expense) Series E Convertible Preferred Stock [Member] Information pertaining to Series E Convertible Preferred Stock. Property, Plant and Equipment, Type [Domain] Conversion of Series C Preferred Stock Into Common Stock [Member] Represents the information pertaining to the conversion of series C preferred stock into common stock. Net loss Net loss govx_ConvertiblePreferredStockConversionPrice1 Convertible Preferred Stock, Conversion Price1 Conversion price related to convertible preferred stock. ASSETS Interest income us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total liabilities Commitments (Note 8) us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other current assets us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net decrease in cash and cash equivalents us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net (Note 5) Property and equipment, net Property and equipment, gross Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Conversion from Series C and F Convertible Preferred Stock to Common Stock [Member] Related to a conversion. Fractional shares issuable upon reverse stock split (in shares) Stock issued as fractional shares during the period as a result of a reverse stock split. Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member] Related to a conversion. Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member] Related to a conversion. us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Total adjustments Cash flows from investing activities: Net proceeds from sale of preferred stock Retained Earnings [Member] Earnings Per Share [Text Block] Accrued directors’ fees Carrying value as of the balance sheet date of the obligations incurred through that date and payable for current directors fees. govx_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCost Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost The cash inflow from issuance of callable preferred stock, after deductions of certain expenses, which is identified as being convertible to another type of financial security at the option of the issuer or the holder. us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock Accounts payable and accrued expenses us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights us-gaap_OperatingExpenses Total operating expenses us-gaap_DebtInstrumentTerm Debt Instrument, Term General and administrative us-gaap_LeaseAndRentalExpense Operating Leases, Rent Expense, Total Term Notes [Member] Represents information about Term Notes. Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense govx_StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices Stock Issued During Period, Value Expensed During the Period, Issued for Services govx_NumberOfSeriesCAndSeriesEPreferredStockExchangedForSeriesFConvertiblePreferredStock Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock Represents number of series C and series E preferred stock exchanged for series F convertible preferred stock. Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member] Represents conversion of series C and series E preferred stock into series F preferred stock. Series F Convertible Preferred Stock [Member] Represents information about Series F Convertible Preferred Stock. Conversion of Series F Preferred Stock Into Common Stock [Member] Represents information about conversion of series F preferred stock into common stock. Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Series G Convertible Preferred Stock [Member] Represents Series G Preferred Stock. govx_ConvertiblePreferredStockConversionPricePercentageOfVolumeWeightedAveragePriceOfTheCommonStock Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock Represents the conversion price pf convertible preferred stock represented as percentage of volume weighted average price of the common stock. Series I Warrants [Member] Represents Series I Warrants. Amendment Flag govx_ProceedsFromIssuanceOfConvertiblePreferredStockAndRelatedWarrantsMaximum Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum Represents the maximum amount of proceeds from issuance of convertible preferred stock and related warrants during the period. Series G Convertible Preferred Stock and Related Warrants [Member] Represents information about series G convertible preferred stock and related warrants. Accounting Policies [Abstract] Significant Accounting Policies [Text Block] govx_ConvertiblePreferredStockAndRelatedWarrantsIssued Convertible Preferred Stock and Related Warrants Issued Represents number of convertible preferred stock and related warrants issued during the period. Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member] Represents series G Convertible Preferred Stock were issued in exchange for cancellation of term notes payable. govx_ConvertiblePreferredStockAndRelatedWarrantsAuthorized Convertible Preferred Stock and Related Warrants, Authorized Represents number of convertible preferred stock and related warrants authorized for issuance. Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance Title of 12(b) Security Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Series D Convertible Preferred Stock [Member] Information pertaining to Series D Convertible Preferred Stock. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Basis of Accounting [Text Block] Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Nonmonetary Transaction Type [Domain] govx_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice govx_ClassOfWarrantOrRightIssuedDuringPeriod Class Of Warrant Or Right Issued During Period Number of Shares Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company govx_ClassOfWarrantOrRightExercisableNumber Class Of Warrant Or Right Exercisable Number ClassOfWarrantOrRightExercisableNumber Nonmonetary Transaction Type [Axis] govx_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice Document Information [Line Items] Document Information [Table] Common Stock Purchase Warrants [Member] Represents information relating to common stock purchase warrants. us-gaap_AreaOfRealEstateProperty Area of Real Estate Property Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] govx_UnusedGrantFunds Unused Grant Funds The amount of grant funds available for use. Research Agreements [Member] Research Agreements [Member] Weighted averages shares outstanding (in shares) us-gaap_IncreaseDecreaseInReceivables Grant funds and other receivables us-gaap_RepaymentsOfNotesPayable Principal repayment of note payable us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Proceeds from issuance of note payable Proceeds from Notes Payable, Total Stock option expense Loss per common share (in dollars per share) Entity Central Index Key Entity Registrant Name EX-101.PRE 11 govx-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2019	Aug. 13, 2019
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		2,477,584
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 216,411	$ 259,701
Grant funds and other receivables	64,246	121,814
Prepaid expenses and other current assets	39,139	238,189
Total current assets	319,796	619,704
Property and equipment, net (Note 5)	11,827	11,350
Deposits	11,010	11,010
Total assets	342,633	642,064
Current liabilities:
Accounts payable	116,207	125,859
Accrued expenses (Note 6)	1,510,268	1,238,552
Current portion of notes payable (Note 7)	12,500	260,420
Total current liabilities	1,638,975	1,624,831
Note payable, net of current portion (Note 7)	32,291	39,580
Total liabilities	1,671,266	1,664,411
Commitments (Note 8)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value: Authorized shares – 10,000,000 Issued and outstanding shares – 3,402 and 3,450 at June 30, 2019 and December 31, 2018, respectively (Note 9)	2,337,867	1,971,333
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 813,916 and 437,807 at June 30, 2019 and December 31, 2018, respectively	814	438
Additional paid-in capital	38,165,172	37,482,766
Accumulated deficit	(41,832,486)	(40,476,884)
Total stockholders’ equity (deficiency)	(1,328,633)	(1,022,347)
Total liabilities and stockholders’ equity (deficiency)	$ 342,633	$ 642,064

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	3,402	3,450
Preferred stock, shares outstanding (in shares)	3,402	3,450
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	813,916	437,807
Common stock, shares outstanding (in shares)	813,916	437,807

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Grant and collaboration revenue	$ 209,941	$ 93,265	$ 574,173	$ 314,564
Operating expenses:
Research and development	451,227	372,202	1,006,945	859,196
General and administrative	412,650	359,197	922,714	716,425
Total operating expenses	863,877	731,399	1,929,659	1,575,621
Loss from operations	(653,936)	(638,134)	(1,355,486)	(1,261,057)
Other income (expense):
Interest income	881	1,716	2,105	3,034
Interest expense	(1,093)	(625)	(2,221)	(833)
Total other income (expense)	(212)	1,091	(116)	2,201
Net loss	$ (654,148)	$ (637,043)	$ (1,355,602)	$ (1,258,856)
Basic and diluted:
Loss per common share (in dollars per share)	$ (1.01)	$ (2.05)	$ (2.37)	$ (4.50)
Weighted averages shares outstanding (in shares)	649,486	310,419	571,032	279,551

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	3,670	213,474
Balance at Dec. 31, 2017	$ 1,899,085	$ 213	$ 35,696,435	$ (37,916,790)	$ (321,057)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	600
Sale of convertible preferred stock for cash and cancellation of note payable	$ 590,000				590,000
Conversion of preferred stock to common stock (in shares)	(450)	60,000
Conversion of preferred stock to common stock	$ (441,000)	$ 60	440,940
Stock option expense			23,978		23,978
Net loss				(621,813)	(621,813)
Issuance of common stock for services (in shares)		10,000
Issuance of common stock for services		$ 10	199,990		200,000
Balance (in shares) at Mar. 31, 2018	3,820	283,474
Balance at Mar. 31, 2018	$ 2,048,085	$ 283	36,361,343	(38,538,603)	(128,892)
Balance (in shares) at Dec. 31, 2017	3,670	213,474
Balance at Dec. 31, 2017	$ 1,899,085	$ 213	35,696,435	(37,916,790)	(321,057)
Net loss					$ (1,258,856)
Issuance of common stock for services (in shares)					10,000
Balance (in shares) at Jun. 30, 2018	3,475	329,474
Balance at Jun. 30, 2018	$ 1,709,985	$ 329	36,722,618	(39,175,646)	$ (742,714)
Balance (in shares) at Mar. 31, 2018	3,820	283,474
Balance at Mar. 31, 2018	$ 2,048,085	$ 283	36,361,343	(38,538,603)	(128,892)
Conversion of preferred stock to common stock (in shares)	(345)	46,000
Conversion of preferred stock to common stock	$ (338,100)	$ 46	338,054
Stock option expense			23,221		23,221
Net loss				(637,043)	$ (637,043)
Issuance of common stock for services (in shares)					0
Balance (in shares) at Jun. 30, 2018	3,475	329,474
Balance at Jun. 30, 2018	$ 1,709,985	$ 329	36,722,618	(39,175,646)	$ (742,714)
Balance (in shares) at Dec. 31, 2018	3,450	437,807
Balance at Dec. 31, 2018	$ 1,971,333	$ 438	37,482,766	(40,476,884)	(1,022,347)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 404,250		85,750		490,000
Conversion of preferred stock to common stock (in shares)	(767)	118,280
Conversion of preferred stock to common stock	$ (303,475)	$ 118	303,357
Fractional shares issuable upon reverse stock split (in shares)		402
Fractional shares issuable upon reverse stock split
Stock option expense			26,652		26,652
Net loss				(701,454)	(701,454)
Balance (in shares) at Mar. 31, 2019	3,183	556,489
Balance at Mar. 31, 2019	$ 2,072,108	$ 556	37,898,525	(41,178,338)	(1,207,149)
Balance (in shares) at Dec. 31, 2018	3,450	437,807
Balance at Dec. 31, 2018	$ 1,971,333	$ 438	37,482,766	(40,476,884)	(1,022,347)
Net loss					$ (1,355,602)
Issuance of common stock for services (in shares)					4,127
Balance (in shares) at Jun. 30, 2019	3,402	813,916
Balance at Jun. 30, 2019	$ 2,337,867	$ 814	38,165,172	(41,832,486)	$ (1,328,633)
Balance (in shares) at Mar. 31, 2019	3,183	556,489
Balance at Mar. 31, 2019	$ 2,072,108	$ 556	37,898,525	(41,178,338)	(1,207,149)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 438,700		61,300		500,000
Conversion of preferred stock to common stock (in shares)	(281)	253,300
Conversion of preferred stock to common stock	$ (172,941)	$ 254	172,687
Fractional shares issuable upon reverse stock split (in shares)
Fractional shares issuable upon reverse stock split
Stock option expense			26,664		26,664
Net loss				(654,148)	$ (654,148)
Issuance of common stock for services (in shares)		4,127			4,127
Issuance of common stock for services		$ 4	5,996		$ 6,000
Balance (in shares) at Jun. 30, 2019	3,402	813,916
Balance at Jun. 30, 2019	$ 2,337,867	$ 814	$ 38,165,172	$ (41,832,486)	$ (1,328,633)

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (1,355,602)	$ (1,258,856)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,795	9,930
Stock-based compensation expense	258,396	132,913
Changes in assets and liabilities:
Grant funds and other receivables	57,568	59,758
Prepaid expenses and other current assets	(30)	41,695
Accounts payable and accrued expenses	262,064	252,802
Total adjustments	581,793	497,098
Net cash used in operating activities	(773,809)	(761,758)
Cash flows from investing activities:
Purchase of property and equipment	(4,272)
Net cash used in investing activities	(4,272)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	740,000	590,000
Proceeds from issuance of note payable		50,000
Principal repayment of note payable	(5,209)
Net cash provided by financing activities	734,791	640,000
Net decrease in cash and cash equivalents	(43,290)	(121,758)
Cash and cash equivalents at beginning of period	259,701	312,727
Cash and cash equivalents at end of period	$ 216,411	$ 190,969

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member]
Convertible note, shares issued (in shares)	250
Convertible note, value	$ 250,000
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,563
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,200
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)	2,763
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	587
Conversion of stock, shares issued (in shares)	78,280
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	461	293,300
Conversion of stock, shares issued (in shares)	293,300
Conversion From Series D Convertible Preferred Stock To Common Stock [Member]
Convertible preferred stock (in shares)		795
Conversion of stock, shares issued (in shares)		106,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business	6 Months Ended
Note 1 - Description of Business	Jun. 30, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (Modified Vaccinia Ankara Virus-Like Particle, or “MVA-VLP”). Our recombinant MVA vector expresses target proteins on highly immunogenic VLPs in the person being vaccinated, resulting in durable immune responses while providing the safety characteristics of the replication-defective MVA vector. Important attributes of GeoVax vaccines include single dose, no adjuvant, durable immunity, extensive safety and cost-effective manufacturing. Our current development programs are focused on preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV); preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa fever), Zika virus and malaria; a therapeutic vaccine for chronic hepatitis B virus infections; and preventive and therapeutic vaccines for multiple solid tumor cancers. Our most advanced vaccine program is focused on the clade B subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan and Australia; this program is currently undergoing human clinical trials. Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners. GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in metropolitan Atlanta, Georgia.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation	6 Months Ended
Note 2 - Basis of Presentation	Jun. 30, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying condensed consolidated financial statements at June 30, 2019 and for the three -month and six -month periods ended June 30, 2019 and 2018 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10 -K for the year ended December 31, 2018. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. As described in Note 10, effective April 30, 2019, we enacted a one -for- five hundred reverse stock split of our common stock. The accompanying financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split. Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve -month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities. We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 13 will be sufficient to continue our planned operations into the first quarter of 2020. Due to our history of operating losses and our continuing need for capital to conduct our research and development activities, there is substantial doubt concerning our ability to operate as a going concern beyond that date. We are currently exploring sources of capital through additional government grants and corporate collaborations. We also intend to secure additional funds through sales of our equity securities or by other means. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern. Additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we will be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 to our consolidated financial statements included in our Annual Report on Form 10 -K for the year ended December 31, 2018 those accounting policies that we consider significant in determining our results of operations and financial position. Other than as described below, there have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10 -K. In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2016 - 02, Leases (ASU 2016 - 02 ). ASU 2016 - 02 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to classify leases as either financing or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to prior guidance for operating leases. We adopted ASU 2016 - 02 effective January 1, 2019; such adoption had no material impact on our financial statements, given that the noncancelable term of our current lease is less than 12 months (see Note 8 ). There have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2019, as compared to the recent accounting pronouncements described in our Annual Report on Form 10 -K for the fiscal year ended December 31, 2018, which we expect to have a material impact on our financial statements.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Basic and Diluted Loss Per Common Share	6 Months Ended
Note 4 - Basic and Diluted Loss Per Common Share	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Loss Per Common Share Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled 376,130 and 351,684 shares for the three -month and six -month periods ended June 30, 2019, respectively, as compared to 51,270 and 51,155 shares for the three -month and six -month periods ended June 30, 2018, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

Property and Equipment

Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of

June 30, 2019

and

December 31, 2018:

	June 30, 2019			December 31, 2018
Laboratory equipment	$	534,578		$	530,306
Leasehold improvements		115,605			115,605
Other furniture, fixtures & equipment		28,685			28,685
Total property and equipment		678,868			674,596
Accumulated depreciation and amortization		(667,041	)		(663,246	)
Property and equipment, net	$	11,827		$	11,350

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Accrued Expenses

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Expenses

Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of

June 30, 2019

and

December 31, 2018:

	June 30, 2019		December 31, 2018
Accrued management salaries	$	1,128,425	$	924,509
Accrued directors’ fees		361,470		295,670
Other accrued expenses		20,373		18,373
Total accrued expenses	$	1,510,268	$	1,238,552

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Notes Payable	6 Months Ended
Note 7 - Notes Payable	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable On February 28, 2018, we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a five -year Senior Promissory Note (the “GRA Note”) to GRA in exchange for $50,000. The GRA Note bears an annual interest rate of 5%, payable monthly, with principal repayments beginning in the second year. Principal repayments are expected to be $6,250 for the remainder of 2019, $12,500 in 2020, 2021 and 2022, and $2,083 in 2023. Interest expense related to the GRA Note for the three -month and six -month periods ended June 30, 2019 was $586 and $1,207, respectively, as compared to $625 and $833, respectively, for the same periods of 2018. On December 27, 2018, we issued short-term non-interest-bearing Term Promissory Notes (the “Term Notes”) to two current investors in exchange for an aggregate of $250,000. In February 2019, the Term Notes were cancelled in exchange for shares of our convertible preferred stock (see Note 9 ).

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Commitments	6 Months Ended
Note 8 - Commitments	Jun. 30, 2019
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2019, with annual extension options through December 31, 2022. Rent expense for the for the three -month and six -month periods ended June 30, 2019 was $40,316 and $80,633, respectively, as compared to $39,136 and $78,273, respectively, for the same periods of 2018. Future minimum lease payments total $80,633 for the remainder of 2019. Our current intention is to exercise our option to extend the lease at least for the subsequent one -year renewal period, subject to our landlord’s right to cancel the extension period 90 days prior to its commencement. Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of June 30, 2019, there are approximately $459,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2019. We expect this entire amount to be reimbursable to us pursuant to existing government grants.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Preferred Stock

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Preferred Stock [Text Block]

Preferred Stock

Prefer

red Stock

Summary

We are authorized to issue up to

10,000,000

shares of our Preferred Stock,

$.01

par value, which

may

be issued in

one

or more series. The table below presents our issued and outstanding series of preferred stock as of

June 30, 2019

and

December 31, 2018.

Each series of our outstanding preferred stock has a stated value of

$1,000

per share. Further details concerning each series of preferred stock, and the changes in each series during the

three

-month and

six

-month periods ending

June 30, 2019

and

2018

are discussed in the sections that follow the table.

	June 30, 2019				December 31, 2018
			Carrying				Carrying
	Shares		Value		Shares		Value
Series B Convertible Preferred Stock		100		76,095		100		76,095
Series C Convertible Preferred Stock		-		-		2,150		705,238
Series E Convertible Preferred Stock		-		-		1,200		1,190,000
Series F Convertible Preferred Stock		2,302		1,418,822		-		-
Series G Convertible Preferred Stock		1,000		842,950		-		-
Total		3,402		2,337,867		3,450		1,971,333

Series B Preferred Stock

During the

three

-month and

six

-month periods ended

June

30,

2019

and

2018,

there were

conversions or other transactions involving our Series B Convertible Preferred Stock (“Series B Preferred Stock”). As of

June 30, 2019,

there are

100

shares of our Series B Convertible Preferred Stock outstanding. The Series B Preferred Stock

may

be converted at any time at the option of the holder into shares of our common stock at a conversion price of

$175

per share.

Series

Preferred Stock

During

January

and

February 2019,

587

shares of our Series C Convertible Preferred Stock (“Series C Preferred Stock”) were converted into

78,280

shares of our common stock. During

February 2019,

all remaining shares of Series C Preferred Stock (

1,563

shares) were exchanged for Series F Preferred Stock. During the

three

-month and

six

-month periods ended

June

30,

2018,

there were

conversions or other transactions involving our Series C Preferred Stock.

Series

Preferred Stock

During the

three

-month and

six

-month periods ending

June 30, 2018,

345

and

795

shares, respectively, of our Series D Convertible Preferred Stock (“Series D Preferred Stock”) were converted into

46,000

and

106,000

shares, respectively, of our common stock. As of

June 30, 2019,

there are

shares of our Series D Preferred Stock outstanding.

Series

Preferred Stock

March 2018,

we issued

600

shares of our Series E Convertible Preferred Stock (“Series E Preferred Stock”), for net proceeds of

$590,000.

September 2018,

we issued an additional

600

shares of Series E Preferred Stock for net proceeds of

$600,000.

During

February 2019,

all outstanding shares of Series E Preferred Stock (

1,200

shares) were exchanged for Series F Preferred Stock.

Series F Preferred Stock

February 18, 2019,

we entered into Exchange Agreements with holders of our Series C and Series E Preferred Stock, pursuant to which the holders exchanged all shares of Series C and Series E Preferred Stock held by them for an aggregate of

2,763

shares of Series F Convertible Preferred Stock (“Series F Preferred Stock”). Each share of Series F Preferred Stock is entitled to a liquidation preference equal to its

$1,000

stated value, has

voting rights, and is

not

entitled to a dividend. The Series F Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i)

$7.50

per share and (ii)

90%

of the volume weighted average price of the common stock immediately preceding the delivery of a notice of conversion. The Series F Preferred Stock contains price adjustment provisions, which

may,

under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series F Preferred Stock. During the

three

-month and

six

-month periods ending

June 30, 2019,

281

and

461

shares, respectively, of Series F Preferred Stock were converted into

253,300

and

293,300

shares, respectively, of our common stock. As of

June 30, 2019,

there are

2,302

shares of our Series F Preferred Stock outstanding.

Series G Preferred Stock

February 25, 2019,

we entered into a Securities Purchase Agreement with the purchasers identified therein (the “Purchasers”) providing for sale to the Purchasers of an aggregate of up to

1,000

shares of our Series G Convertible Preferred Stock (“Series G Preferred Stock”) and related warrants for gross proceeds of up to

$1.0

million, to be funded at up to

three

different closings. Each share of Series G Preferred Stock is entitled to a liquidation preference equal to its

$1,000

stated value, has

voting rights, and is

not

entitled to a dividend. The Series G Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i)

$7.50

per share and (ii)

90%

of the volume weighted average price of the common stock immediately preceding the delivery of a notice of conversion. The Series G Preferred Stock contains price adjustment provisions, which

may,

At the

first

closing, which occurred on

February 26, 2019,

we issued

500

shares of Series G Preferred Stock in exchange for the payment by the Purchasers of

$250,000

in the aggregate, plus the cancellation of Term Notes held by the Purchasers (see Note

) in the amount of

$250,000.

At the

first

closing we also issued the warrants to purchase an aggregate of

33,334

shares of our common stock. The warrants have an exercise price of

$7.50

per share, are exercisable

six

months from the issuance date, and have a term of exercise equal to

five

years from the date they

first

become exercisable. The warrants contain anti-dilution and price adjustment provisions, which

may,

under certain circumstances reduce the exercise price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then exercise price of the warrants; in the event of such adjustment, the number of shares subject to the warrants will also increase so that the aggregate exercise price remains the same for each warrant. At the

second

and

third

closings, which occurred on

April 26

and

June 19, 2019,

we issued an aggregate of

500

additional shares of Series G Preferred Stock in exchange for the payment by the Purchasers of a total of

$500,000

We also issued the Purchasers warrants to purchase an aggregate of

66,668

shares of our common stock. As of

June 30, 2019,

there are

1,000

shares of our Series G Preferred Stock outstanding.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Common Stock and Stock-based Compensation	6 Months Ended
Note 10 - Common Stock and Stock-based Compensation	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Common Stock and Stock-Based Compensation Reverse Stock Split Following approval by our shareholders at a meeting held on April 15, 2019, on April 30, 2019, we effected a one -for- five hundred reverse split of our common stock by the filing of an amendment to our certificate of incorporation with the State of Delaware. All share and per share information in our condensed consolidated financial statements and notes that relate to our common stock has been retroactively restated to reflect the reverse stock split. Common Stock Transactions As discussed in Note 9, during the three -month and six -month periods ended June 30, 2019, we issued 253,300 and 371,580 shares, respectively, of our common stock pursuant to conversions our Series C and Series F Preferred Stock. During the three -month and six -month periods ended June 30, 2018, we issued 46,000 and 106,000 shares, respectively, of our common stock pursuant to conversions our Series D Preferred Stock. During the three -month and six -month periods ended June 30, 2019, we issued 4,127 shares of our common stock in exchange for consulting services. During the three -month and six -month periods ended June 30, 2018, we issued - 0 - and 10,000 shares, respectively, of our common stock in exchange for investment banking and financial advisory services. See “Stock-Based Compensation Expense” below. Stock Options During the six months ended June 30, 2019, there were no transactions involving our stock option plans. As of June 30, 2019, there are 29,441 stock options outstanding ( $53.19/share weighted-average exercise price), 13,585 of which are exercisable at that date ( $93.92/share weighted-average exercise price). Stock Purchase Warrants During the six months ended June 30, 2019, we issued an aggregate of 100,002 stock purchase warrants in connection with the sale of our Series G Preferred Stock as discussed above. As of June 30, 2019, there are 294,302 stock purchase warrants outstanding ( $7.50/share weighted-average exercise price), 194,300 of which are exercisable at that date ( $7.50/share weighted-average exercise price). Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $26,664 and $53,316 during the three -month and six -month periods ended June 30, 2019, respectively, as compared to $23,221 and $47,199, respectively, during the same periods of 2018. Stock-based compensation expense related to stock options is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of June 30, 2019, there was $157,067 of unrecognized compensation expense related to stock options, which we expect to recognize over a weighted average period of 1.9 years. During the three -month and six -month periods ended June 30, 2019 we recorded stock-based compensation expense of $78,509 and $205,080, respectively, associated with common stock issued for consulting and financial advisory services, as compared to $57,143 and $85,714, respectively, during the same periods of 2018.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes	6 Months Ended
Note 11 - Income Taxes	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Because of our historically significant net operating losses, we have not paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits will be subject to substantial annual limitations due to ownership change provisions of Section 382 of the Internal Revenue Code. The annual limitation will result in the expiration of net operating losses and credits before utilization.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Grants and Collaboration Revenue	6 Months Ended
Note 12 - Grants and Collaboration Revenue	Jun. 30, 2019
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three -month and six -month periods ended June 30, 2019, we recorded $184,938 and $539,257, respectively, of revenues associated with these grants and contracts, as compared to $93,265 and $309,564, respectively, for the comparable periods of 2018. As of June 30, 2019, there is an aggregate of $2,049,990 in approved grant funds available for use during 2019 and 2020. During the three -month and six -month periods ended June 30, 2019, we recorded $25,003 and $34,916, respectively, of revenues associated with research collaboration agreements with third parties, as compared to $5,000 for the comparable periods of 2018.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Subsequent Events	6 Months Ended
Note 13 - Subsequent Events	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Events Stock Transactions On July 16, 2019, we entered into Exchange Agreements with holders of our Series F and Series G Preferred Stock, pursuant to which the holders exchanged all shares of Series F and Series G Preferred Stock held by them for an aggregate of 3,257 shares of Series H Convertible Preferred Stock (“Series H Preferred Stock”). Each share of Series H Preferred Stock is entitled to a liquidation preference equal to its $1,000 stated value, has no voting rights, and is not entitled to a dividend. The Series H Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) $7.50 per share and (ii) 80% of the lowest volume weighted average price of the common stock during the ten trading days immediately preceding the delivery of a notice of conversion. The Series H Preferred Stock contains price adjustment provisions, which may, under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series F Preferred Stock. On July 24, 2019, we entered into a Securities Purchase Agreement with the purchasers identified therein (the “Purchasers”) providing for sale to the Purchasers of an aggregate of 700 shares of our Series I Convertible Preferred Stock (“Series I Preferred Stock”) for gross proceeds of $700,000. Each share of Series I Preferred Stock is entitled to a liquidation preference equal to its $1,000 stated value, has no voting rights, and is not entitled to a dividend. The Series I Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, at a conversion price equal to the lesser of (i) $7.50 per share and (ii) 80% of the lowest volume weighted average price of the common stock during the ten trading days immediately preceding the delivery of a notice of conversion. The Series I Preferred Stock contains price adjustment provisions, which may, under certain circumstances reduce the conversion price to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the then conversion price of the Series I Preferred Stock. During July and August 2019, holders of our preferred stock converted 46 shares of our Series F Preferred Stock into 88,400 shares of our common stock and 171 shares of our Series H Preferred Stock into 1,737,441 shares of our common stock. During August 2019, we issued 37,827 shares of our common stock in exchange for consulting services.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

	June 30, 2019			December 31, 2018
Laboratory equipment	$	534,578		$	530,306
Leasehold improvements		115,605			115,605
Other furniture, fixtures & equipment		28,685			28,685
Total property and equipment		678,868			674,596
Accumulated depreciation and amortization		(667,041	)		(663,246	)
Property and equipment, net	$	11,827		$	11,350

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 6 - Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	June 30, 2019		December 31, 2018
Accrued management salaries	$	1,128,425	$	924,509
Accrued directors’ fees		361,470		295,670
Other accrued expenses		20,373		18,373
Total accrued expenses	$	1,510,268	$	1,238,552

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 9 - Preferred Stock (Tables)

6 Months Ended

Jun. 30, 2019

Notes Tables

Schedule of Preferred Stock [Table Text Block]

	June 30, 2019				December 31, 2018
			Carrying				Carrying
	Shares		Value		Shares		Value
Series B Convertible Preferred Stock		100		76,095		100		76,095
Series C Convertible Preferred Stock		-		-		2,150		705,238
Series E Convertible Preferred Stock		-		-		1,200		1,190,000
Series F Convertible Preferred Stock		2,302		1,418,822		-		-
Series G Convertible Preferred Stock		1,000		842,950		-		-
Total		3,402		2,337,867		3,450		1,971,333

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation (Details Textual)	Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	500

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	376,130	51,270	351,684	51,155

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 678,868	$ 674,596
Accumulated depreciation and amortization	(667,041)	(663,246)
Property and equipment, net	11,827	11,350
Laboratory Equipment [Member]
Property and equipment, gross	534,578	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accrued management salaries	$ 1,128,425	$ 924,509
Accrued directors’ fees	361,470	295,670
Other accrued expenses	20,373	18,373
Total accrued expenses	$ 1,510,268	$ 1,238,552

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Notes Payable (Details Textual) - USD ($)		3 Months Ended		6 Months Ended
Note 7 - Notes Payable (Details Textual) - USD ($)	Feb. 28, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 27, 2018
Proceeds from Notes Payable, Total					$ 50,000
Interest Expense, Total		$ 1,093	$ 625	2,221	833
Term Notes [Member]
Debt Instrument, Face Amount						$ 250,000
Senior Notes [Member]
Debt Instrument, Term	5 years
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year		6,250		6,250
Long-term Debt, Maturities, Repayments of Principal in Year Two		12,500		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Three		12,500		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Four		12,500		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Five		2,083		2,083
Interest Expense, Total		$ 586	$ 625	$ 1,207	$ 833

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Commitments (Details Textual)	3 Months Ended		6 Months Ended
Note 8 - Commitments (Details Textual)	Jun. 30, 2019 USD ($) ft²	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) ft²	Jun. 30, 2018 USD ($)
Area of Real Estate Property \| ft²	8,400		8,400
Operating Leases, Rent Expense, Total	$ 40,316	$ 39,136	$ 80,633	$ 78,273
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 80,633		$ 80,633
Lessee, Operating Lease, Renewal Term	1 year		1 year
Unrecorded Unconditional Purchase Obligation, Total	$ 459,000		$ 459,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 9 - Preferred Stock (Details Textual) - USD ($)						1 Months Ended			2 Months Ended	3 Months Ended		6 Months Ended
Note 9 - Preferred Stock (Details Textual) - USD ($)	Jun. 19, 2019	Apr. 26, 2019	Feb. 26, 2019	Feb. 25, 2019	Feb. 18, 2019	Feb. 28, 2019	Sep. 30, 2018	Mar. 31, 2018	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Preferred Stock, Shares Authorized										10,000,000		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share										$ 0.01		$ 0.01		$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance										3,402		3,402		3,450
Series I Warrants [Member]
Convertible Preferred Stock and Related Warrants Issued			33,334
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			66,668
Series G Warrants [Member]
Warrants and Rights Outstanding, Term			5 years
Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized				1,000
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum	$ 500,000	$ 500,000	$ 250,000	$ 1,000,000
Convertible Preferred Stock and Related Warrants Issued	500	500	500
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted									587			587
Conversion of Stock, Shares Issued									78,280			78,280
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted						1,563						1,563
Conversion of Series D Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted											345		795
Conversion of Stock, Shares Issued											46,000		106,000
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted						1,200						1,200
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted										281	253,300	461	293,300
Conversion of Stock, Shares Issued												293,300
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share										$ 1,000		$ 1,000
Conversion of Stock, Shares Converted										0	0	0	0
Preferred Stock, Shares Outstanding, Ending Balance										100		100		100
Convertible Preferred Stock, Conversion Price1										$ 175		$ 175
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share										$ 1,000		$ 1,000
Conversion of Stock, Shares Converted											0		0
Preferred Stock, Shares Outstanding, Ending Balance														2,150
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance										0		0
Series E Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share										$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance														1,200
Stock Issued During Period, Shares, New Issues							600	600
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost							$ 600,000	$ 590,000
Series F Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share					$ 1,000					$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance										2,302		2,302
Convertible Preferred Stock, Conversion Price1					$ 7.50
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock					2,763
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock					90.00%
Series G Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 1,000						$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance										1,000		1,000
Convertible Preferred Stock, Conversion Price1				$ 7.50
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock				90.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 9 - Preferred Stock - Preferred Stock Summary (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, shares outstanding (in shares)	3,402	3,450
Preferred Stock	$ 2,337,867	$ 1,971,333
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	100	100
Preferred Stock	$ 76,095	$ 76,095
Series C Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)		2,150
Preferred Stock		$ 705,238
Series E Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)		1,200
Preferred Stock		$ 1,190,000
Series F Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	2,302
Preferred Stock	$ 1,418,822
Series G Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	1,000
Preferred Stock	$ 842,950

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 10 - Common Stock and Stock-based Compensation (Details Textual)		3 Months Ended		6 Months Ended
	Apr. 30, 2019	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) shares	Jun. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) shares
Stock Issued During Period, Shares, Issued for Services		4,127	0	4,127	10,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		29,441		29,441
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance \| $ / shares		$ 53.19		$ 53.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		13,585		13,585
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price \| $ / shares		$ 93.92		$ 93.92
Share-based Payment Arrangement, Expense \| $		$ 26,664	$ 23,221	$ 53,316	$ 47,199
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total \| $		157,067		$ 157,067
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				1 year 328 days
Stock Issued During Period, Value Expensed During the Period, Issued for Services \| $		$ 78,509	$ 57,143	$ 205,080	$ 85,714
Common Stock Purchase Warrants [Member]
Class Of Warrant Or Right Issued During Period				100,002
Class of Warrant or Right, Outstanding		294,302		294,302
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price \| $ / shares		$ 7.50		$ 7.50
Class Of Warrant Or Right Exercisable Number		194,300		194,300
Class Of Warrant Or Right Exercisable Weighted Average Exercise Price \| $ / shares		$ 7.50		$ 7.50
Conversion from Series C and F Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued		253,300		371,580
Conversion of Series D Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued			46,000		106,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	500

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 209,941	$ 93,265	$ 574,173	$ 314,564
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	184,938	93,265	539,257	309,564
Unused Grant Funds	2,049,990		2,049,990
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 25,003	$ 5,000	$ 34,916	$ 5,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 13 - Subsequent Events (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		6 Months Ended
Note 13 - Subsequent Events (Details Textual) - USD ($)	Aug. 12, 2019	Jul. 24, 2019	Jul. 16, 2019	Jul. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Preferred Stock, Par or Stated Value Per Share					$ 0.01		$ 0.01		$ 0.01
Stock Issued During Period, Shares, Issued for Services					4,127	0	4,127	10,000
Subsequent Event [Member]
Stock Issued During Period, Shares, Issued for Services	37,827
Subsequent Event [Member] \| Series H Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share			$ 1,000
Convertible Preferred Stock, Conversion Price1			$ 7.50
Subsequent Event [Member] \| Series I Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 1,000
Convertible Preferred Stock, Conversion Price1		$ 7.50
Stock Issued During Period, Shares, New Issues		700
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 700,000
Conversion from Series F and Series G Preferred Stock to Series H Preferred Stock [Member] \| Subsequent Event [Member]
Conversion of Stock, Shares Issued			3,257
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued							293,300
Conversion of Stock, Shares Converted					281	253,300	461	293,300
Conversion of Series F Preferred Stock Into Common Stock [Member] \| Subsequent Event [Member]
Conversion of Stock, Shares Issued				88,400
Conversion of Stock, Shares Converted				46
Conversion of Series H Preferred Stock Into Common Stock [Member] \| Subsequent Event [Member]
Conversion of Stock, Shares Issued	1,737,441
Conversion of Stock, Shares Converted	171

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 132 226 1 false 36 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://geovax.com/20190630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://geovax.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://geovax.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://geovax.com/20190630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) Sheet http://geovax.com/20190630/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-deficiency-unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://geovax.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) Sheet http://geovax.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited-parentheticals Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Description of Business Sheet http://geovax.com/20190630/role/statement-note-1-description-of-business- Note 1 - Description of Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Basis of Presentation Sheet http://geovax.com/20190630/role/statement-note-2-basis-of-presentation Note 2 - Basis of Presentation Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements Sheet http://geovax.com/20190630/role/statement-note-3-significant-accounting-policies-and-recent-accounting-pronouncements Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share Sheet http://geovax.com/20190630/role/statement-note-4-basic-and-diluted-loss-per-common-share Note 4 - Basic and Diluted Loss Per Common Share Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Property and Equipment Sheet http://geovax.com/20190630/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Accrued Expenses Sheet http://geovax.com/20190630/role/statement-note-6-accrued-expenses- Note 6 - Accrued Expenses Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Notes Payable Notes http://geovax.com/20190630/role/statement-note-7-notes-payable Note 7 - Notes Payable Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Commitments Sheet http://geovax.com/20190630/role/statement-note-8-commitments Note 8 - Commitments Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Preferred Stock Sheet http://geovax.com/20190630/role/statement-note-9-preferred-stock Note 9 - Preferred Stock Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Common Stock and Stock-based Compensation Sheet http://geovax.com/20190630/role/statement-note-10-common-stock-and-stockbased-compensation Note 10 - Common Stock and Stock-based Compensation Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Income Taxes Sheet http://geovax.com/20190630/role/statement-note-11-income-taxes Note 11 - Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Grants and Collaboration Revenue Sheet http://geovax.com/20190630/role/statement-note-12-grants-and-collaboration-revenue Note 12 - Grants and Collaboration Revenue Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Subsequent Events Sheet http://geovax.com/20190630/role/statement-note-13-subsequent-events- Note 13 - Subsequent Events Notes 20 false false R21.htm 020 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://geovax.com/20190630/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://geovax.com/20190630/role/statement-note-5-property-and-equipment 21 false false R22.htm 021 - Disclosure - Note 6 - Accrued Expenses (Tables) Sheet http://geovax.com/20190630/role/statement-note-6-accrued-expenses-tables Note 6 - Accrued Expenses (Tables) Tables http://geovax.com/20190630/role/statement-note-6-accrued-expenses- 22 false false R23.htm 022 - Disclosure - Note 9 - Preferred Stock (Tables) Sheet http://geovax.com/20190630/role/statement-note-9-preferred-stock-tables Note 9 - Preferred Stock (Tables) Tables http://geovax.com/20190630/role/statement-note-9-preferred-stock 23 false false R24.htm 023 - Disclosure - Note 2 - Basis of Presentation (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-2-basis-of-presentation-details-textual Note 2 - Basis of Presentation (Details Textual) Details http://geovax.com/20190630/role/statement-note-2-basis-of-presentation 24 false false R25.htm 024 - Disclosure - Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-4-basic-and-diluted-loss-per-common-share-details-textual Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) Details http://geovax.com/20190630/role/statement-note-4-basic-and-diluted-loss-per-common-share 25 false false R26.htm 025 - Disclosure - Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://geovax.com/20190630/role/statement-note-5-property-and-equipment-schedule-of-property-and-equipment-details Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) Details 26 false false R27.htm 026 - Disclosure - Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://geovax.com/20190630/role/statement-note-6-accrued-expenses-schedule-of-accrued-expenses-details Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) Details 27 false false R28.htm 027 - Disclosure - Note 7 - Notes Payable (Details Textual) Notes http://geovax.com/20190630/role/statement-note-7-notes-payable-details-textual Note 7 - Notes Payable (Details Textual) Details http://geovax.com/20190630/role/statement-note-7-notes-payable 28 false false R29.htm 028 - Disclosure - Note 8 - Commitments (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-8-commitments-details-textual Note 8 - Commitments (Details Textual) Details http://geovax.com/20190630/role/statement-note-8-commitments 29 false false R30.htm 029 - Disclosure - Note 9 - Preferred Stock (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-9-preferred-stock-details-textual Note 9 - Preferred Stock (Details Textual) Details http://geovax.com/20190630/role/statement-note-9-preferred-stock-tables 30 false false R31.htm 030 - Disclosure - Note 9 - Preferred Stock - Preferred Stock Summary (Details) Sheet http://geovax.com/20190630/role/statement-note-9-preferred-stock-preferred-stock-summary-details Note 9 - Preferred Stock - Preferred Stock Summary (Details) Details 31 false false R32.htm 031 - Disclosure - Note 10 - Common Stock and Stock-based Compensation (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-10-common-stock-and-stockbased-compensation-details-textual Note 10 - Common Stock and Stock-based Compensation (Details Textual) Details http://geovax.com/20190630/role/statement-note-10-common-stock-and-stockbased-compensation 32 false false R33.htm 032 - Disclosure - Note 12 - Grants and Collaboration Revenue (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-12-grants-and-collaboration-revenue-details-textual Note 12 - Grants and Collaboration Revenue (Details Textual) Details http://geovax.com/20190630/role/statement-note-12-grants-and-collaboration-revenue 33 false false R34.htm 033 - Disclosure - Note 13 - Subsequent Events (Details Textual) Sheet http://geovax.com/20190630/role/statement-note-13-subsequent-events-details-textual Note 13 - Subsequent Events (Details Textual) Details http://geovax.com/20190630/role/statement-note-13-subsequent-events- 34 false false All Reports Book All Reports govx-20190630.xml govx-20190630.xsd govx-20190630_cal.xml govx-20190630_def.xml govx-20190630_lab.xml govx-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 51 0001437749-19-016606-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-19-016606-xbrl.zip M4$L#!!0 ( '"+#4^K' &2-V4 )6.!0 1 9V]V>"TR,#$Y,#8S,"YX M;6SMO6MWXT:N*/K]KG7^ Z]WYIS.6I*;3Y'L3/HLM[O=X[TS;9_N3G+F?LFB MR9+%"44J?/BQ?_T%JDB)E%@2*9$497/6))%%J@I 2@ A0+^_K^?YI[P0,+( M#?R?SZ1S\4P@OATXKG__\]FOW\87WRZOK\^$*+9\Q_("G_Q\Y@=G__O]__A_ M_O[_CL>?B4]"*R:.GN]!SW^&_!8# C^A']^>S61POWKU]^_CX>([?G ?A_5M9 M%)6WKH\PV.2,O5_]S7=VD/AQ^+S\!7T[(O;Y??#P-GT(OY3TL2B-%6GYLR0, M@12\WZ5/2W[H$+?\-_#@+:-"_G7R9,_*W\E$P3 MA2M:3:WHCHX/7Y8L610O0L[0\*1D[)B)A@.B4<#CZ\?/5RZ0Z#["%3J+Q MO64M-J%)'Y1 E,0A=Q',M_#T+"=FSAI_IN]-WK*'RU]*IFF^I4^7 MKT9E[\&8TMO_^\]?OMDS,K?&ZW+Y%+EU?@4J1Q#^CK.^B^BCKV0J4"C>S4(R M_?D,Y6*<"<'Y4^21/[^=F.=>@*Y[^BSS7F030$>%_AB*K1DK$TC$W MI@SF\\#_%@?VG]]F5DBBFR2FFSTHI<+\[A^K#?Q,<(CMSD$"?CZ[_G*U1%0^ M$Q+?9>_3_7P67VMA)+&@*[:,NCXU[ PDO 06O _"6E." M=OH"VZ%EV\1+S3,Z5AZ"PN#K,W\E]VX$7./'7ZQY+5X'5O],@M^L)^$7ZRX: M"=>^?9Z?MCCR^KS?9L3S]J&Q4D+C_& ;$P'O>A^2R/5)5$]-26?OXS I3I0? M;#73-P(V(CR6Y+OO;NS54QG KDP^!"H@;+KU$5=S?0\M%)MOS_.[P*LS$6A= MW#;9^(51V.#X\-V%;0/*SDB(U M)\<)[-?OE8FDZJ"-=TV[+W &VTNW B?S@)--;5(3N$O/BJ*;Z>]6B"Q_$WYU M[V?QIR<2VFYDW7GD2S*_(R&7B'^4_O[BR8W&.>UYFX3V#$SL]*WHGP0'W8*C M,M&YBEHR547,D*P&?@U\?R?X!7$NP..T[DGZA-R"U4ZZIX)1OM+C!0G'1:KH MYUI5FFQ#<1>EKJ,(>0J$W+]G1D@566Z-/BJ?2]#6D+=19!.574@$XZF"> &/=@I-#0,$X%(\+W_E*/-S;,TPNDG@6A.Y_DW*FD<>R MEO^(Y@Y!0_337PFSQA:!3W F_H1")'?JCF$X(M(A6V&X^[TC1#Z M6)KL),0_=A#BCV_)743^2E#C/*0Q./;SXO<[R:9*^QF%1R";K.XDVW5G9)/5 MOI$-?!,;0 <3_&;Z6^ E\W4'CKYU,_T^(SDOHANE)155UN;6M4A"/#=K M$FH_I(]-W88U89&ZIM(?ZGX.X#T?T?Q,C0SP&&&*.+3L./H.=/G@K1-I:Y0O MDF1#,R;FV?O_Z<4_.>Z#$,7/'H%?N='"LY[?":[ON3[Y29C"D..I-7<]^#)V MYR02?/(HA,'<\M.G$;A;[P1)7,1G__,^_FEMQ,((_^L['>$+C/ 51_A?(X%^ M,Q(B6*SI3ZOQ<+B?YA:&Q-_A1\1K;'GNO?_.(]/XI[*IRH%_I)1^)]P%GE/C M9_0A?!?#I/;:4*X_ W#CXIM^$ (7L1DD^1PG>0NST FM^>(G_RY:5/[$5EF M918N \^S[H+0BH&;A*\$U&I""J/G/@M=4G\%]Y$@^)T((;&)^T"$A?6,TA$) M4V!-X7XI+@+!@#SH 8$>MPM!$@KWC+CTS7A&A"^4M)8G7/L1O)S$1 BFPH7G MD?#^F:[!M3\E-KR41,)'-R)6!..]^7)]/W*>2N1I,=LH3N!Y ?)4$>F8A3DMYNE^$%3S)&LZ:/"W" )"Q0T$('G$8I)RN[1 M!K\#NX),W:_4I)UMAR/D?!L/^8"]A3CH AE3&Q8 ^&"Y'ETV7,D$V-YA*KN3I3./P-6R*(OG M@XF#M0NNBP5*EC CG;[6!3^[H5- M @USEQS%1L#%+"K\WFW,O,]IM*-2$"(7M&"Y(#=3%HBYO/ =]NE3,5;RZ M6?X]<:Z"<%=$C'/@*!F=G1)L!H66"8WZ1$DIU0+F.;K>AH%-B!-=@=>)ITV8 M"WTSK7,H9CVY\V3>UZ0 SD%,FF.R/)-KB@P=4O;8"02<(PK@7>V$"=N#PW:3 M1UCME#GV^(?SDG@BA/U"XIMI]MYE$,6;!#7&HI(&X^E'1=JY4WTZ8*>:\'G2 MW)]T&WBV33)S13*S2BK$(233N5G(DP.X;1O)\$:3DWCP\^)OOJ,UN,?!CCU6 MVCK3B:F!>H?>3_CS&%E.(G5Y,#*X:K)W_\]EDN7"Y>(2 IY-V;+ :XLG(0H\UQ'"^[LWX);C_W_,+5>K@9@4;SI; M(3"P$0_JRT(.'-1?#OI(;+H'"8I$N<@X$A<)J=K.DVC7"K^-P\.4: M?N87I7'VJ"PP WCM@]>%/GA=%#VBFI?/^K?XFYO!$;3\)?B4SZ!=*RKWOB[T M -Z@%T^6HH->'/1B&PM]L!7\&AU">7 (.2+!JIP71 M*JN<59%'4CREOQW1V>T1#+#8!57CO0)0VI6AO0ERXL^&8FF=K#('&?)!\'J(Z2#8#6U$9VR5!V; M"_L PTLWMAK:/([.P(WX<)I&W;<.?;B>>FV7@].F\*X\D[:7&RX[-.WV X:7SKRYJ([E8^.@T.?A$3Y%ZZH%\&CR0 M09,,5EP?^*8/, R\._#NJ<+PTGE7&LDO]L3^V+S3!QA>/O]*IKA>$NPT>7@X M!6G2![D:?)!!E]2-QBFB?/IZI)>\TP<87CK_2B-5,D:&//#PP,.GRL.#+SWP M[L"[I^V##.<@J0_R>?!!NKYZ>&Q54PN?#BS"7D9&JM&HGQMO2PQ[0J .LD5G M,%1Y9 [9.\->,\A#7ZW?89\Y95 'N>JK7)65:1B.NX[C:GX/@*L&7[),;A60 M6R=(T/=^&8IH.T*M:R)EI/;Q?*PBD4YCFV^*9T\)UD&^?LK.GQ5]9$ST_LE8 M+V6G#S ,,M'ZGM/'&,NPYYPXK(-\92<$IB[!OJ/T3\;6O4SE4"_S+>V]M42P MV)6U6@NQ?,\Q?(K]R(C#NDO?$FPZRPIY?B7@R$:$OO-MX;EQ=(7]7=W MSSV MQJYF9,7&=J6= LO[LBT;L1F&KO.ZK I/T3O?]7X^B\.$G+WM%5KPYSSP*_6: M Q1-;B-9<%:RM3T,IY:IHQ8[T!VXZ*;$I4BWBUX/K9)%S^$D2XWA1.N;?GI: M$#_*'GR?$?:,O)T3=T$1S.WO6@K0+Q#=:)6Y!7.&V MR!4UT1!/"7-CM>1&![#!(VV/LOI+8 G_ ^62%/DP? ME:'%VXF.B5810MZ6T2F$#1MC,5 ^CRM)ORB?(A+NEWY1Y1LDQ MT2I"R+,>^!#^ZB=@+'S&QO-7B>\4YW3S]+L- R>QXYO,@J!D^W+]C\^L:?VN MAN:*R>T!+XOPAIF9L^L0,6"3:'QO68MW%[8=)##?K?6,,84+WX%O "GG%]>Z MQLLEY M(4BVBCE5_)0NMY#:N=%&R"U_@M\5L8N1LR- D%&%I%01K$B(9L&C+P2^$,^( M8('6CTWO,*'>H4X"?J)).: :'>&#Y5F^381O,T+B2'!1&8"2Q/>"*1UE M&GA>\(A#P/CP7?OL(A0ZG0MY^EJ^TP4 &XVRW_6?Y59!9U22:;3\YS-0<3;Q MO#0FO/P[6EAV]G<*>AHA#AF1M+^MQ8PE8Q&7!)L/C5Y33%WD31J7QD@U3)F& MQW51S!K9"-7RG3K+9*IR9-+]Q$.?IIU]FC+ETJT4YR% K58Q\:SO&:>]A6\0 MA)ULF-_DCBH,QK&$X?5U39L87?=,R^?=;B3G%NQ8&-ZZI]ZZ$(%5BA=!A_3< M+4ED/^P&1GGA%\>E$7CN(U5^ :T\!FY^]=QLRNI($\W3Y^7AADJC&Z/CAL2. M@S"BD_S'$_H/,"X9]L<]87CIBD292"-5[V'V[[ I#BQ<\4J'J8TF+X&%3]1A M[-M>>!,#P^")1N'(8]C_VKSQ?C0=TZ][Y+(X4O0>IOD/11I.&M1!NE@(Q^BG M= VE&OJS^=-2#)F&(!Z^\3. M-TEUA7=1Y[TD3611YT*> M3KH?8,98DNE-B"V <;./)5DS-+,V8&M$WI]HIL2_]"7!+@.;3 &X\HGWAF\G M[0"^"9]VB@%BN2]\W]*C_4.(I_,75I(-5=8V@%N;=3_(JI"-=VWEO2FK].)J M3<"2>>)AHNY'L@AA5@OO"L!GC^ '%/UY ,[$?]/O;\-@ :[%\ZUG^3$\PTL/ MB_G>1.;>QYQ,=%&5"J@T F97R%=81YTKGI.)(JN3UI$OOWB3NV&TEZKFLZ=B M2!--TO-BO1.$PT&NH,2YUPK?*[IJR/ID<@C(_TZB&*D??0\X/Z;7P@<3[J,7PFL6^3&)+T8P^[X?"5V<._34>AUGRZNR7(WDM+[/R>$^8Z[M/H+ M17O'E3M^00^#:X;)DTEAOVZ9""='\BJW@'D61^_9;1O+F-SMX/6Q3,/WEY5: M%T=/"//MEYP5GMMPZFCOJY9-A;=1H8Q-U$'&#KF>S0T]])[=MK(,_];TZV*9 M8AV=PZUE4Q1/1"W7QGR;6@:T3T0MUT9[3[4,%.&K9<74C4'&]E?+0-P34V^UK'#CKK(BR](@8X>H MY5-QSFK5C12W.%B]81E\U;==CWPA\;5O!W/R2Q#!]Y=6-+L-@P?7(IQU85%2<<$FD&9)N*AP:'0AUE_2H57%3G'!#I:JI MBR9O*V^6'IX7V'AJ1%GNPSK+I:6.#JVC.ZGL2E8"IS$4:E3$U;E!2DU1I,EQ M4*A7VE;G%_5=4U'=HE"C2"W_-%C5)=,\$ 4_=AW72T!20,7:24CEY=.3[24@ M4E=A,,6;Z_T.*[F5%1Y MHN2-+SI)M8FKI+_Q0<6%Z5+BX4M;T''P<)3 M;<7+PNU/N<N;X%C9'E"E,4H(L&*CU\J=!J$M(9I M^X#$LY"0_/3C.;PY$[HI6!JY3R5S+VB8(A((+%HG95./7;=UHY8<6!F@^ZW$ M<8%-1\)=$L,@U#P1+,\3K)5W/Z(<[494MX,R8,,*(9HU6,0;B!ACGNY(>)RY M]DQX),(=\5SR0(0X@(^@J6T215;X3)G.$J:6&PJ+G$K)ZNFBR$24+[+U2=\B MSKEPC87QW#G,&R4>"E'8!?/Z05P@6X8+J!3XL>."/PBX\NL"G00*#L36JH%?2!:1#X2\O M?#^!-[Z211#&6/KX"C#K@&A2H3C%^+^6R@8)TIW,;90J/B\(WN^$WI>T8TJK M((M*+1<2F'?J)7:< 'V7&,!_@2,)K2,\3>(D!%"Q_@+!!Z.4;\=Q,&:?:,EH MX)8(UBY;[^Z9EG(82*0C) O@ HO*%?!NQKJ(6(8UL [#*Y/!\]>[R5]$8#Q' M=NC>,9GZ$L1=Z!QIK0(OF4X)6ZL.A.9B ;IMN5.-"A(#FIWXEHWZQ^H EL O MF@T@8N/V9YTBH6>)[X"(%)8A9!TJ8&I,V(^P1P4*#RH/FYYELB=,X1=LPS)E M/:+['&ZU-(20[7KI7ZX_19#H1H#N%#V_$E#/N/Y(F%D/N,<2'V"*P\"BS $; M$LAP3'<'4%V@D3S4;4RV-R!_Q5)] PM6NGVNR KJ$;0VLGD4)7-XXK@Z M&/V-IJS7"3[V5K?%4.G@*ZG)!1XV+B.\0CHMALE=_ 8" LR\4P%(Q6NU 9$-0AF3,28.P)+ MPF8^!(Q O(!=:$I_\@#B!V@+-CRG!A.;CR[P-*'V![6L5L=F,"@%>1H&?#GA/V[G0>6R@)-:F$,#:Q9H+$=K$V"&"B3+]961Y),J@(/0P&I@TB_]1 M((H<1)&!]X 2.0)0("E0JQ=G@',.XIX)\-:*&+L@X%W!3F]?Y^]$QS+Z,DQ MT/\]Y]V@3J +_91Z1[85S9 YX4L;9\@Q$JXHTQ/SN1OGMH"42TJ>"R#%=A)% MW1H?A8(SC%OOD#FG4]=V$9,\5U+Y]"P?=Z?4@D9+U_7AI6[4TM0-HZ*U^U=B MA> J=M.0119EL2B*'YE4(V5FP!8!N+VH#Y;NA1=$4>KE,M.!DA*?^(2PN(S- M,BY22F.;*?HJ5^NMM,*(.2/8K":O3K!809QM4=2-1^U'=YEG"BR%KFP_@[5_ M#NA&!;R.&G*IN&T6# 9=#5Z4%]!(0,KXB/ 2AUD8)/< \S*KA*=>@Q#<5(3" MAIW$N@M29F(3>E& 7$5\:MQ0E4KR8Z8*,YULNQH6@,1WL"JT;MZ<6#C'/U<5 MUE/QCHI[/I4!&YU_<.U1'MEXZ7:7@R1#/%7KSKH6%RZ989BO6!N5"!&+R2QU M#+X &B$X@ON(L0RZ(Y,'%]>'&BT;W 4KEL1\!"MQV[EP45Q2?-:!TS.WGC>J M2W3NHEL/ENO1P +8@5/K 00 _P!5-JDN_#L@8U6137$7(N50-8E/O-YRG8VU MN]FHR!$GC%*/BXDL^KF67]U]4*I E2$@GPS7>7&7*)]X7QX7A^M$_I(_-2F M"?S/V$&0ZMA4(,U-$J-EY:QG4A2ZS_)QSUVKN 5C? 9<6IT.$XU+!]E4%5'> M08@<[&N8KKQ:E"UJ#H-!8*]G++L;.2)IJHI6JX7Z7M,NC8#\M'O=OLE-VT3S M777(CVG'"#<.S(_)K?.0%;/GDM'?_4+W^(O[D% 7?"!F&FGT*%VL!;A63Z"R M8SSDZ4 L1JI8.,$7(HRI$>RKPT+L& MD1U9IH :C7-@WEPB+)(P2BX4)+3\? M]Z*XL-,1P])=6&RI Y@4JN*%]-%&,/J%?L_.(V7*CCNF'>+7VR5U$_DIPS.[396BR'>!#'F%U M&0..$*)_T[00=D+E@;AX0>@48_6TL#8]M\#C;8^BLMH9T_/^]A$RBT:(8SUC MXIJ+M U@2*IM@(-M:C/V[#S\%*QNUCAJ<&+6(+C>D7-##U,P*3EDY]P/%O!D M$@E3-YRC^4MC+H5S_)!X65H66/)XGHMR1/-_R#*M.I>W,EH=^TY7YRU1G#CT MB)<>':=-OY;I(,)%1[M+T08JFM+L\)FFLW7LL_R@:N9(7'-;@!Z)'Q(;J_?C M:?LJL%:Z3*E.? "E'H3L4!K4)49K0HLV&1UEYV#+1/1U&R+R4G7! -23'S MA1TXT^X)6Q7R\4L!J(INY%M:[ =;E>./K0#R+^KO)-[6XXOJ4%8AH[D_&:M MN>_)NZ'S"\ 8DEH*5=E1]4Y(*M"(7Z!%58SJD/B8^TYOV>=HR+X&!2E5.8WY M8V.4#\^_^BXX=A_I]1#J$::G;[D7Z2GD9;'"VS58C.S!57GI-WYI'H-_."=I M$R5/D1TX]XQ$GYHC$5\[27)1KY\6B4JXJ*1^'I\P)I]W-$,_7;I<'4J7+7IX M(G5)E\U\EGWH@I5%&&4^II.Y8.P7B?2]%HFD0EW@M5P14^N8=;AELM-T!#I2 M+@?D Y<*.Q&75;X9=D1-(H]EXXB:1-:VU,#I7)/(K=)EOTU(UO@"T_4^O:U4 M)D=B+@^0&(VO33N5F!*T#^",CP=*S(3O<2IJIPJTF3VF,;KT:6-I4),T9L[* M6T(J1S!GU_?>XYEMLL'/UX1GIZMJ#J8+7]7(FJ)TRS+-:IN#2P:TK+: M^^/;,LWDTP/\Z_OS@C"B%K_?24-5WA+=GW1,1&-%1 P6'T+$?W1+1+[\27KC MQ@D[5&D_ 'GA.XU':_F$DO4*CG**>J_(=&@\DB^ NB$;NQ59#VERH.4FB5N, M_6J66R-$Z6^ EA^GA&=B5_3I69B2[PEU*$@]"T3Q#X'4[OBD9T&HW@A/ ^&5 ME7+![?JJ(06CJ ='%7JT*[5%(WYX0=$EK<.=6Q]+D_S'@VATM33[/J^3I]2T M;MJ6EO@14$76=A\W-4?44_7HMJ1#%;L]M$S!DW7G%'Y<0=(5755WNW2E-/Q( M[N+5^TNO[]J/XC#!&$E]=5@.U_>K)GEG]/KH+PDMX#\=)N M)=]).,=J=-&M]8RYQ!7C>N[[EX;>LF\JIDY#?*$LK MYJSN),0FW9JH4J ,50K:R?77#ZQ20/E,2!EMN.)#;SYU$V_+"]^(C[?;:*7/K'C+JBH"ZPCPF02 FR5\S:X%77B>RZK0 M7OOVN?#F\]>+'POW.I:755R6]MU%Z6XLHKUY&3'%[Q8$'F#!F@$4U3?T OOR M!J+]$Z! GZR^MT'=ULD\6ND84YI2,4$< 2'Z,CS/N#/!(-Y2A+JQ25Z'6F)[.R M)KF;LG%>P0YE3EY7F1/P)XXA&-)(%O5^E3B9R-I1JKUL+_72H^(F@Q?3454J M6>=X,:E?$ !6L"K#N?J#1?P\NVGUGEOX/W8F7]C^(O:,AQ&3' '*[F0Y&!N1N$70'%:!D'C(;0-U&TH4C8N M.[BFJ.R!50X1PSA[?ZO]BPG"$, ,-I,-GC]"HO.\ YX(&^>]5S[3]RY^+VH0'J%*XFE(%EB:@KU7L M7-2XQ=M-4Q$/@7Z]3SUV8[#A%Q^QU?U:10E.7L,6_C!D#N EU4_&TGF^^LD. MP [$8C.-9RL6G H*95C(!>W5+A9U1 "PX%1?*,="T3M)Q9;1.*,+? "T(ST:4,%VD8L[:R:N@NYLCO.JOL6 M"T"<+U>F^8EI=]: 5@6E[2D=G E;%^5?HYW&TGXANT"]K368S1JP,[BXKM(H M]9BRTM6T@!W]9EGN[C%M!7&>,>WF7.RX,(^L3=M64RBQ210N+4D57J%E+2M( M34O-LB*%V,$S(=](^.#:)#.6B8-M((D?40W_ M): !5.)
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end